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1 SUMMARY (ENGLISH) 
Background: Following the introduction of conjugate vaccines against invasive Haemophilus 
influenzae type b (Hib) disease in Germany, the incidence of Hib disease dramatically 
decreased. Hib conjugate vaccines were combined with diphtheria, tetanus and acellular 
pertussis antigens (DTaP/Hib) and gradually replaced by higher-valent vaccines, additionally 
incorporating inactivated polio virus and - since the end of 2000 - hepatitis B (DTaP-IPV-
HB/Hib or hexavalent vaccines). Recently, an increasing incidence of invasive Hib disease in 
children and an increasing number of vaccine failures have been reported from some 
European countries, which coincided with the introduction of combination vaccines 
containing the acellular pertussis component. Previous data in Germany showed no such 
increase and vaccine effectiveness (VE) of DTaP/Hib and DTaP-IPV/Hib combination 
vaccines against invasive Hib disease was estimated to be high. Since Germany is the first 
country who introduced hexavalent vaccines, insufficient data on the impact of hexavalent 
vaccines on invasive Hib disease and on the VE against invasive Hib disease in children 
exist.  
 
Aim: To assess (1) annual numbers of Hib cases and vaccine failures of Hib vaccines before 
and after the introduction of hexavalent vaccines in German children, (2) annual incidences 
of invasive Hib disease before and after the introduction of hexavalent vaccines in German 
children and to estimate (3) VE of hexavalent vaccines against invasive Hib disease in 
German children.  
 
Subjects and Methods: Invasive Haemophilus influenzae (Hi) infections in children less 
than 10 years were ascertained from 1998 to 2004 through two independent nation-wide 
active surveillance systems, one hospital- and one laboratory-based. Species confirmation 
and capsular testing was performed in the national consulting laboratory for Hi. Cases were 
defined by any hospitalisation due to a systemic infection clinically compatible with an 
invasive Hi disease and with isolation of Hi from a normally sterile body site. Annual case 
numbers and incidences were adjusted for underreporting and for differences in the 
proportion of typed cases over time. VE was determined with a case-cohort approach using 
Cox regression with time-dependent covariates. In this analysis, Hib cases born between 
August 2000 and June 2003, aged 2 months or older and ascertained from August 2000 to 
December 2003 were included for case-cohort analysis and a ‘sub’-cohort of children born in 
the same time frame as the cases was randomly sampled in a nationwide immunisation 
survey. Children receiving two/three Hib doses (depending on vaccine type) in the first year 
of life, without booster, were defined as ‘fully primed’, children receiving a single dose in the 
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second year of life, regardless of priming, as receiving a ‘2nd year dose’ and children 
receiving a booster dose at the age of 11 months or later following full priming as receiving 
the ‘full immunisation’.  
 
Results: In the two surveillance systems annual response rates since 1998 were >90%, the 
proportion of untyped Hi cases decreased from 25% of all reported cases in 1998 to 15% in 
2004 and the proportion typed in the national consulting laboratory increased from 55% of all 
reported cases in 1998 to 70% in 2004. The annual number of Hi cases decreased from 51 
in 1998 to 27 cases in 2004. Hib cases fluctuated between 28 in 1998 and 4 in 2004. Of all 
117 Hib cases detected since 1998, 64 were not vaccinated and 52 were vaccinated at least 
once. 92% of the unvaccinated Hib cases and 53% of the vaccinated Hib cases could have 
received at least one (additional) dose if timing of general recommendations would have 
been followed. Of all vaccinated Hib cases, 12 had been vaccinated with at least one dose of 
a hexavalent vaccine. Overall annual incidence rates of Hi disease were relatively constant 
throughout the years 1998 through 2004 (0.8-0.4/100,000). Annual incidences of Hib disease 
ranged between 0.3 and 0.1 per 100,000 in 1998 and 2004, respectively, with the highest 
incidence in the 3-11 month age-group (1.7/100,000 in 2003). Adjustment for underreporting 
and differences in typing gave no evidence of an increasing trend of Hib disease in German 
children. Twenty-seven cases were eligible for VE calculation; 17 were unvaccinated and 10 
vaccinated with hexavalent vaccines; of these, 5 received an incomplete primary series, 5 
received the full primary series and none a 2nd year dose or the full immunisation before 
disease onset. In the immunisation survey, response rate was 63% and interviewed 
households were representative for age-eligible children in Germany according to 
geographical and social distributions. 1303 valid interviews of children born from 1 August 
2000 onwards were available. Median age at vaccination with the complete primary series of 
hexavalent vaccines was 6.0 months and 14.4 months for the full immunisation. 
Effectiveness of hexavalent vaccines against invasive Hib infection was 75.5% (95% CI: 
31.4-91.3) for incomplete primary series and 91.8% (95% CI: 73.6-97.5) for the full primary 
series. For the 2nd year dose - but no full immunisation - and full immunisation vaccine 
effectiveness was 100.0% (95% CI: 99.5-100.0 and 99.9-100.0, respectively).  
 
Conclusion: Four years after the introduction of hexavalent vaccines in Germany, there was 
no indication of increasing incidence of invasive Hib disease or increasing number of vaccine 
failures in children. Hexavalent vaccines continue to show the high effectiveness against 
invasive Hib disease observed for other DTaP-containing Hib vaccines in Germany. 
Sustained surveillance – especially for fully immunised children - should confirm protection 
induced by hexavalent vaccines.  
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2 SUMMARY (GERMAN) 
Einleitung 
In Deutschland ist die Inzidenz von invasiven Haemophilus influenzae Typ b (Hib) 
Erkrankungen nach der Einführung von Konjugatimpfstoffen gegen Hib drastisch gesunken. 
Hib-Impfstoffe wurden daraufhin mit anderen Antigenen zu Kombinationsimpfstoffen 
zusammengefasst: zu Beginn mit Diphtherie-, Tetanus- und azellulären Pertussis-Antigenen 
(DTaP/Hib), dann zusätzlich mit inaktivierte Polioviren und – seit Ende 2000 – mit Hepatitis 
B-Antigenen (DTaP-IPV-HB/Hib; hexavalente Impfstoffe). Kürzlich wurden aus anderen 
europäischen Ländern steigende Hib-Inzidenzen und Hib-Impfversager berichtet, die in 
Zusammenhang mit der azellulären Pertussiskomponente von Kombinationsimpfstoffen 
stehen. In Deutschland konnte bislang kein solcher Anstieg festgestellt werden und die 
Wirksamkeit von DTaP/Hib und DTaP-IPV/Hib Kombinationsimpfstoffen gegen invasive Hib 
Erkrankungen ist hoch. Da Deutschland das erste Land war, in dem hexavalente Impfstoffe 
eingeführt wurden, gibt es bislang noch ungenügend Daten über deren Einfluss auf die 
Epidemiologie von invasiven Hib Erkrankungen und die Wirksamkeit dieser Impfstoffe im 
‚Feld’. Ziel dieser Studie war es (1) die Anzahl von Hib Fällen und von Hib-Impfversagern 
und (2) die Jahresinzidenzen von invasiven Hib-Erkrankungen vor und nach der Einführung 
von hexavalenten Impfstoffen bei Kindern in Deutschland zu bestimmen und (3) die 
Wirksamkeit der hexavalenten Impfstoffe gegen invasive Hib Erkrankungen zu berechnen.  
 
Methoden 
Invasive Haemophilus influenzae (Hi) Erkrankungen bei Kindern unter 10 Jahren wurden 
zwischen 1998 und 2004 über zwei unabhängige aktive Surveillance-Systeme in 
Deutschland erhoben. Die Typisierung der Erreger erfolgte im Nationalen Konsiliarlabor für 
Hi in Mainz. Ein Fall wurde definiert als jede Hospitalisierung aufgrund einer systemischen 
Infektion, die klinisch vereinbar mit einer invasiven Hi Infektion war und einen 
Erregernachweis aus normalerweise sterilen Körperflüssigkeiten hatte. Jährliche Fallzahlen 
und Inzidenzen wurden für Untererfassung und Unterschiede im Anteil der typisierten Fälle 
korrigiert. Die Impfstoff-Wirksamkeit wurde mit der ‚Case-Cohort’ Methode und 
zeitabhängigen Kovariablen im Cox-Modell ermittelt. Hierbei wurden alle Hib Fälle, die 
zwischen August 2000 und Juni 2003 geboren und mindestens 2 Monate alt waren, 
eingeschlossen und deutschlandweite Telephoninterviews zum Impfstatus von Kindern, die 
im selben Zeitrahmen geboren wurden, durchgeführt. Kinder, die je nach Impfstofftyp zwei 
oder drei Hib-Impfdosen im ersten Lebensjahr ohne nachfolgenden ‚Booster’ erhielten, 
werden als ‚vollständig grundimunisiert’, Kinder, die eine Dosis im zweiten Lebensjahr, 
unabhängig von der Anzahl vorangegangener Dosen, als ‚immunisiert mit Dosis im 2. 
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Lebensjahr’, und Kinder, die die vollständige Grundimmunisierung und einen Booster im 
Alter von 11 Monaten oder später erhielten als ‚vollständig immunisiert’ definiert.  
 
Ergebnisse 
Die jährlichen Response-Raten der beiden Surveillance-Systeme betrugen >90%, der Anteil 
untypisierter Hi Fälle sank von 25% im Jahr 1998 auf 15% im Jahr 2004 und der Anteil der 
Fälle, die im Nationalen Konsiliarlabor typisiert wurden stieg von 55% aller Fälle im Jahr 
1998 auf 70% im Jahr 2004. Die jährliche Anzahl der Hi Fälle sank zwischen 1998 und 2004 
von 51 auf 27 Fälle, die der Hib Fälle schwankte zwischen 28 und 4 pro Jahr. Von allen 117 
Hib Fällen, die seit 1998 detektiert wurden, waren 64 nicht und 52 zumindest einmal gegen 
Hib geimpft. 92% der ungeimpften und 53% der geimpften Hib Fälle hätten mindestens eine 
weitere Dosis zum Zeitpunkt ihrer Erkrankung erhalten sollen, wenn die Empfehlungen der 
Ständigen Impfkommission in Deutschland eingehalten worden wären. Zwölf der geimpften 
Hib Fälle erhielten mindestens eine Dosis eines hexavalenten Impfstoffes. Die 
Jahresinzidenzen von Hi blieben zwischen 1998 und 2004 relativ konstant (0,8-0,4/100.000), 
Die Jahresinzidenzen von Hib schwankten zwischen 0,3 und 0,1 pro 100.000, mit den 
höchsten Werten für die Altersgruppe der 3-11 Monate alten Kinder (1,7/100.000 im Jahr 
2003). Auch Korrekturen bezüglich Untererfassung oder Typisierungs-Anteil gaben keinen 
Anhalt für eine Zunahme von invasiven  Hib-Infektionen in Deutschland. Für die Berechnung 
der Wirksamkeit von hexavalenten Impfstoffen konnten 17 ungeimpfte und 10 geimpfte 
Kinder (5 unvollständig grundimmunisiert, 5 vollständig immunisiert) mit Hib Erkrankung 
aufgenommen werden. Die Responserate aus den Telephoninterviews betrug 63% und die 
interviewten Haushalte waren bezüglich geographischer und sozialer Parameter 
repräsentativ für entsprechende Kinder in Deutschland. Insgesamt waren 1303 Interviews 
verfügbar. Das mediane Alter zur vollständigen Grundimmunisierung betrug 6,0, das zur 
vollständigen Immunisierung 14,4 Monate. Die Wirksamkeit der hexavalenten Impfstoffe 
gegen invasive Hib-Erkrankungen betrug 75,5% (95% CI: 31,4-91,3) für unvollständig 
grundimmunisierte Kinder und 91,8% (95% CI: 73,6-97,5) für vollständig grundimmunisierte 
Kinder. Für Kinder, die vollständig oder im 2. Lebensjahr immunisiert wurden, war der 
Impfstoff zu 100,0% wirksam (95% CI: 99,5-100,0 bzw. 99,9-100,0).  
 
Schlussfolgerung 
Vier Jahre nach der Einführung von hexavalenten Impfstoffen in Deutschland gibt es keinen 
Hinweis für steigende Hib-Inzidenzen oder steigende Anzahl von Hib-Impfversagern. 
Hexavalente Impfstoffe weisen eine hohe Wirksamkeit gegen invasive Hib Erkrankungen bei 
Kindern auf, die vergleichbar mit denen anderer DTaP-enthaltender Hib-Impfstoffe ist. Eine 
längere Surveillance-Periode erscheint jedoch insbesondere zur Beurteilung der Wirksamkeit 
von vollständig immunisierten Kindern sinnvoll.  
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3 INTRODUCTION 
Prior to the development of effective vaccines, Haemophilus influenzae type b (Hib) was the 
most common single organism causing invasive bacterial infections in children in the 
developed world (Tudor-Williams et al., 1989; Murphy et al., 1992; Wenger et al., 1992). In 
most European countries, the annual incidence rate of invasive Hib in children less than five 
years ranged between 20 and 50 per 100,000 (e.g. Reinert et al., 1993; Hargreaves et al., 
1996; Takala et al., 1989; Tozzi et al., 1997; van Alphen et al., 1997). Following the 
introduction of conjugate vaccines against Hib in July 1990 in Germany, the incidence of Hib 
disease decreased sharply (von Kries et al., 1997). Similar patterns were observed in other 
European countries (Garpenholt et al., 1996; Hargreaves et al., 1996), the US (Adams et al., 
1993) and Australia (Herceg, 1997).  
 
Because Hib conjugate vaccines are usually administered at the same time as diphtheria, 
tetanus and pertussis vaccines, combination vaccines were developed to improve 
compliance and reduce health care costs. The first diphtheria-tetanus-acellular pertussis 
(DTaP) / Hib conjugate combination vaccines were licensed for primary vaccination and have 
been available to physicians in Germany since October 1996. Other DTaP/Hib conjugate 
vaccines in combinations incorporating inactivated poliovirus vaccine (IPV) have 
subsequently been registered in 1998 in response to a recommendation of the German 
Vaccine Advisory Board (Ständige Impfkommission am Robert-Koch Institut = STIKO) to 
switch from oral polio virus (OPV) to IPV in January 1998. DTaP-based Hib vaccines were 
widely used in Germany: within one year of availability, over 70% of all Hib vaccinations in 
children were being given as combinations containing DTaP (Institute for Medical Statistics, 
Munich, personal communication, 2005).  
 
Concerns have been raised in some countries over the use of DTaP/Hib conjugate 
combinations following the demonstration that DTaP/Hib conjugate combination vaccines elicit 
lower antibody levels to Hib polysaccharide after the primary vaccination series when 
compared with administration of the same Hib conjugate vaccine injected separately, either as a 
separate injection concomitantly with DTaP or alone. Nevertheless, 95% of DTaP/Hib conjugate 
vaccines had an antibody response to Hib >0.15µg/mL, the minimum protective concentration 
for anti-Hib antibody level which is generally correlated to protection against Hib (Eskola et al., 
1996; Pichichero et al., 1997; Schmitt, 1995; Shinefield et al., 1997). A comparison of anti-Hib 
antibody titres achieved with Hib conjugate vaccines in recent combination vaccines to those 
seen in studies with licensed monovalent Hib conjugate vaccines suggest that slightly lower 
Haemophilus influenzae type b – Epidemiology and Vaccine Effectiveness in Germany H. Kalies 
 
   6 
titres may not translate into reduced clinical efficacy (Eskola et al., 1999). In addition, other 
markers of Hib immunity (functional capacities of antibodies, immune memory, booster 
responses, etc.) showed no difference between separate and combined administration of this 
component (Eskola et al., 1999; Bell et al., 1998; Zepp et al., 1997; Poolman et al., 2001). The 
clinical relevance of this lower antibody response has therefore been questioned (Eskola et 
al., 1999).  
 
Despite the spectacular success of Hib conjugate vaccines in the developed world (Peltola, 
2000), an increasing number of vaccine failures have recently been reported from the 
Netherlands (Rijikers et al., 2003) and the United Kingdom. In the UK, the incidence of 
invasive Hib disease at age 0-4 years increased from 0.65 per 100,000 in 1998 to 4.58 per 
100,000 in 2002 (Ramsay et al., 2003). This increase has been seen to coincide with the 
change from whole cell pertussis to acellular pertussis Hib combination vaccines and with the 
introduction of concomitant meningococcal group C vaccine (Trotter et al., 2003). The 
effectiveness of these DTaP/Hib vaccines following full priming was only 56.7% (Ramsay et 
al., 2003). This resulted in the withdrawal of DTaP/Hib vaccines and implementation of a 
national immunisation catch-up campaign for children younger than 4 years in the UK (Health 
Protection Agency, 2004). In Germany, however, the effectiveness of DTaP/Hib and DTaP-
IPV/Hib vaccines has been estimated to be high (Schmitt et al., 2001; Kalies et al., 2004).  
 
At the end of 2000, Germany was the first country where hexavalent vaccines were 
introduced by adding a hepatitis B (HBV) component to the previous pentavalent DTaP-
IPV/Hib combination. Again, these vaccines gained rapid acceptance; the average market 
share of the two licensed vaccines (Hexavac®; Infanrix hexa®) increased from 63% of all Hib 
vaccines in 2001, 83% in 2002 and 87% in 2003 to 88% in 2004 (Institute for Medical 
Statistics, Munich, personal communication, 2005). Apart from two conference abstracts 
(Kalies et al., 2003, 2005), there are no data published describing numbers of Hib cases or 
Hib incidences or estimating the effectiveness of hexavalent vaccines against invasive Hib 
disease after licensure of these vaccines. Therefore, evaluating whether hexavalent Hib 
vaccines are as effective as lower-valent Hib vaccines in preventing invasive Hib disease in 
Germany remains an important issue, not only for regulatory authorities but also for the 
public.  
 
This study aims to assess the impact of the introduction of the two hexavalent DTaP-IPV-
HBV/Hib conjugate combination vaccines on invasive Hib disease in Germany, and to 
estimate the effectiveness of hexavalent vaccines against invasive Hib disease in children. 
The objectives of this study are presented in detail in the following section.  
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4 OBJECTIVES OF THE STUDY 
(1) To describe annual numbers of Hib cases and vaccine failures of Hib vaccines 
against invasive Hib disease in German children before and after the introduction of 
hexavalent combination vaccines on the German market. 
 
(2) To describe annual incidence of invasive H. influenzae and Hib disease in German 
children before and after the introduction of hexavalent combination vaccines on the 
German market.  
 
(3) To estimate the effectiveness of hexavalent combination vaccines against invasive 
Hib disease in German children:  
 
(a) after incomplete primary series;  
(b) after complete primary series;  
(c) after complete primary series followed by a booster dose at the age of 11 
months or later (‘fully immunised’);  
(d) after receiving a dose in the second year of life regardless of priming (‘2nd year 
dose’), excluding category c; 
 
(e) after any number of vaccinations but not according to the recommended 
schedule; 
(f) after an immunisation according to the recommended schedule.  
 
Definitions of vaccine effectiveness, the different categories of vaccination status and the 
recommended Hib vaccination schedule are given in detail in chapters 6.1 and 6.4.4.  
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5 STRUCTURE OF THE DOCUMENT 
This study is structured in a ‘material and methods’ section (chapter 6) where general 
definitions, the surveillance system for detection of H. influenzae (Hi) cases, the national 
immunisation survey for evaluation of the immunisation status in the German population and 
the statistics used are described.  
 
The ‘results’ section is subdivided into five chapters. In the first chapter (chapter 7.1), the 
quality of the surveillance system to detect H. influenzae cases and of the national 
immunisation survey to detect the Hib immunisation status of German children – which is 
necessary to answer objective 3 – will be described. In the second chapter (chapter 7.2), a 
general description of the data derived from these two systems is given; to reflect a situation 
where hexavalent combination vaccines dominated the German market, this section is 
restricted to the time period of the years 2001-2004 for the case surveillance system and to 
children born after 30 July 2000 for the immunisation survey. In the next three chapters, the 
above objectives of the study will be answered; in chapters 7.3 and 7.4, cases or incidences 
of cases detected in the years 2001-2004 will be compared to a time period before 
hexavalent combination vaccines have been licensed. In chapter 7.5 the effectiveness of 
hexavalent vaccines against invasive Hib disease is reported; here, cases detected in 2004 
could not be considered for effectiveness calculations because the national immunisation 
survey collected data on children born up to 31 December 2003 only.  
 
The ‘discussion’ section (chapter 8) debates meanings of these results in the context of other 
data.  
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6 MATERIAL AND METHODS 
6.1 Definitions 
6.1.1 Recommended Hib vaccination schedule  
In Germany, the immunisation calendar is recommended by the German Standing 
Committee on Vaccination (Ständige Impfkommission am Robert Koch-Institut; STIKO). 
Children are vaccinated by paediatricians or family physicians who can choose any of the 
vaccines licensed for immunisation of infants and children. In the study period, 15 different 
products were available for Hib vaccination in children. The recommended schedule for all 
Hib vaccines containing acellular pertussis components is a 3-dose primary series at age 2, 
3 and 4 months with a booster dose scheduled at 11-14 months. For vaccines not containing 
acellular pertussis a 2-dose primary series at age 2 and 4 months is recommended (Robert 
Koch Institute, 2003). As brand names were asked for a distinction between the completion 
of these two primary schedules could be made. For children vaccinated with Hib vaccines 
who did not receive full priming and booster by the age of 12 months, a single Hib dose in 
the second year of life is recommended. 
 
6.1.2 Categories of vaccination status  
According to the recommended German vaccination schedule for Hib the following two 
definitions with mutually exclusive vaccination categories were defined:  
 
(1) Completeness of vaccination schedule 
- Incomplete primary series: after receiving one dose of a Hib vaccine not containing 
acellular pertussis or after receiving 1-2 doses of a Hib vaccine containing acellular 
pertussis in the first year of life and no further doses at age 11 or later.  
- Complete primary series: after receiving at least two doses (vaccines not containing 
acellular pertussis) or three doses (vaccines containing acellular pertussis) of Hib 
vaccines in the first year of life and no further doses at age 11 or later.  
- 2nd year dose: after receiving a booster dose at the age of 11 months or later following 
complete primary series, or any dose in the second year of life regardless of priming.  
A specification of the latter category is:  
o Full immunisation: after receiving a booster dose at the age of 11 months or 
later following complete primary series (=full priming).  
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(2) Age-eligibility of vaccination schedule 
- Immunised according to recommended schedule: 
o Receiving a 2nd year dose or full immunisation; 
o Receiving full primary series and less than 16 months old at disease onset; 
o Receiving incomplete primary series and less than 6 month old at disease 
onset;  
o Not immunised and less than 2 months old at disease onset. 
- Immunised not according to recommended schedule:  
o Receiving a full primary series and 16 or more months old at disease onset; 
o Receiving incomplete primary series and 6 month or more old at disease 
onset; 
o Not vaccinated with a Hib vaccine and 2 months or older at disease onset. 
This definition is less stringent than the recommended vaccination schedule: for the 
incomplete primary series, children were defined as being immunised age-appropriate if 
they were less than 6 months old at disease onset, even if they should have received 
more doses until this age by applying the exact timing of the recommended vaccination 
schedule.  
 
6.1.3 Vaccine failures 
The following definition for vaccine failures with mutually exclusive categories was chosen:  
 
- Vaccine failure of the incomplete primary schedule: invasive Hib disease in a child 
occurring at least 1 week after incomplete primary Hib vaccine series (single doses given 
at least 1 month apart) and prior to a dose completing primary schedule or a 2nd year 
dose.  
 
- Vaccine failure of the complete primary schedule: invasive Hib disease in a child 
occurring at least 1 week after complete primary Hib vaccine series (single doses given 
at least 1 month apart) and prior to a booster dose given at an age ≥ 11 months.  
 
- Vaccine failure of a 2nd year dose: invasive Hib disease occurring at least 1 week after a 
dose of vaccine given at the age of 11 months or later following full priming or any dose 
in the second year of life, irrespective of the total number of doses given.  
A specification of the latter category is:  
o Vaccine failure of the primary and booster regimen: invasive Hib disease 
occurring at least 1 week after complete primary Hib vaccine series (single 
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doses given at least 1 month apart) and after a booster dose given at an 
age of 11 months or later.  
 
6.2 H. influenzae cases in Germany 
To assess valid numbers and incidences of invasive Hib disease in Germany a reliable 
nationwide surveillance system was used: national active surveillance of invasive 
Haemophilus influenzae disease in children less than 16 years of age was performed 
through the ‘Erhebungseinheit für Seltene Pädiatrische Erkrankungen in Deutschland (ESPED)’ 
(Schmidt et al., 1993).  
 
6.2.1 Case definition 
A case of invasive Haemophilus influenzae infection was defined as any hospitalisation due to a 
systemic infection clinically compatible with an invasive H. influenzae disease (e.g., 
meningitis, pneumonia, epiglottitis, septicaemia [all cases of bacteraemia without a reported 
focus were classified as septicaemia since they were all hospitalised], cellulitis, arthritis) and 
with isolation of H. influenzae from a normally sterile body site such as blood or 
cerebrospinal fluid. All cases occurring in children less than 10 years of age are analysed in 
this study.  
 
6.2.2 ‚Erhebungseinheit für Seltene Pädiatrische Erkrankungen in 
Deutschland’ (ESPED) 
ESPED was established in July 1992, adapted from the British Paediatric Association 
Surveillance Unit (Schmidt et al., 1993) with the primary purpose of epidemiological 
surveillance. ESPED evaluated the effect of vaccination on invasive H. influenzae disease 
incidence over the period from July 1992 to December 1995. As shown in other countries, 
vaccination against Hib greatly reduced the incidence of disease in Germany (von Kries et al., 
1997) to such an extent that Hib surveillance was dropped from the ESPED programme at the 
end of 1995. National active surveillance of invasive H. influenzae disease was reintroduced 
in 1998.  
 
Before 1998, the active surveillance system was based on monthly report cards sent to all 
hospital paediatric departments in Germany; from 1998 onwards an additional system was 
established based on reports from laboratories performing microbiological analyses.  
Haemophilus influenzae type b – Epidemiology and Vaccine Effectiveness in Germany H. Kalies 
 
   12 
 
6.2.2.1 Clinical ESPED 
As part of the established national clinical surveillance system, monthly report cards were 
routinely sent to the heads of all known hospital paediatric departments in Germany (range: 
388-393 hospital departments per year). The geographic distribution of these hospitals in 
1998 to 1999 is shown in figure 1 (green dots). The cards solicit information on the number of 
patients hospitalised with any one of up to 12 listed rare diseases / serious adverse events 
(annex A.1, chapter 15.1). Invasive H. influenzae disease was reinstated to this list in 
January 1998. Case reports were followed up by means of a questionnaire mailed to the 
reporting paediatrician, requesting information on age, sex, and nationality of the patient, the 
clinical history including any underlying risk factors for invasive Hib disease, results of 
diagnostic procedures including serotyping of H. influenzae isolates, clinical management, 
outcome and Hib vaccination history with type / brand of vaccine and number of doses 
administered (annex A.2, chapter 15.1). If necessary, additional information was obtained 
through telephone interviews of paediatricians.  
 
6.2.2.2 Laboratory ESPED 
In 1997, the Robert-Koch-Institute of the German Ministry of Health, located in Berlin, 
established an independent laboratory surveillance system (Laboratory ESPED). The 
surveillance mechanism was similar to that of Clinical ESPED with monthly report cards 
being sent to all laboratories known at that time to be performing microbiological analysis on 
specimens of any origin from paediatric hospital departments throughout Germany (range: 
290-295 laboratories per year). The geographic distribution of these hospitals in 1998 to 
1999 is shown in figure 1 (red dots). Invasive H. influenzae disease, defined as isolation of H. 
influenzae from a normally sterile body fluid such as blood or cerebrospinal fluid, was added 
to the report card in January 1998. The monthly report card requested details about the age 
of the patient, the clinical origin of the specimen, and bacterial serotype (annex A.3, chapter 
15.1). In addition vaccination histories and, from 2001 onwards, information on concomitant 
medical conditions as well as outcome was obtained by questionnaire or telephone calls to 
the respective paediatrician for all reported cases of invasive H. influenzae disease.  
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Figure 1: Clinics and laboratories involved in the ESPED surveillance in 1998-1999. 
(Hospitals are marked in Green, laboratories in Red) 
 
 
Response rates for both Clinical ESPED and Laboratory ESPED surveillance surveys were 
measured by the number of surveillance cards/questionnaires returned over the number of 
cards/questionnaires sent out.  
 
6.2.2.3 Matching of the two sources and identification of the duplicates 
Cases reported to Clinical- and Laboratory-ESPED were matched using personal identifiers 
(initials, sex, birth date, geographical region, type of isolate and time of recording) to exclude 
any duplicate reporting of the same cases by the two systems. Matching was performed by 
Robert Koch Institute (Berlin, Germany) and Institute of Social Paediatrics (University 
Munich, Germany) independently. Cases with discordant matching results were double 
checked by both parties and final decision was agreed upon full information of the two 
possible duplicates.  
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6.2.2.4 Serotyping and final classification 
Culture, identification and serotyping of clinical isolates by slide agglutination were performed 
in the local laboratories participating in the ESPED programme according to their routine 
procedures. Local laboratories also performed Polymerase Chain Reaction testing (PCR) 
when available. Laboratories were encouraged to send their specimens to the national 
H. influenzae consulting laboratory at the Department of Paediatric Infectious Diseases, 
Johannes-Gutenberg-University, Mainz, Germany (Prof. Dr. H-J. Schmitt), where typing of H. 
influenzae isolates is performed by slide agglutination using a commercial kit (Haemophilus 
influenzae Agglutinating Sera (a-f); Murex Biotech Ltd., Dartford, UK) and by the PCR 
method described by Falla et al. (1994). This method was recommended by Dr. Mary Slack 
(project leader of the European Union Invasive Bacterial Infections Surveillance Network 
[EU-IBIS]), to be used in all European reference laboratories. If slide agglutination and PCR 
results are discordant, PCR results are considered final.  
 
Cases are classified as type b based on the following criteria: if samples for the case were 
not sent to the national consulting laboratory, local typing results are considered final; if 
samples for the case were sent to the reference laboratory, the national consulting laboratory 
results are considered final.  
 
6.3 National immunisation survey 
To estimate the effectiveness of hexavalent DTaP-HBV-IPV/Hib combination vaccines 
against invasive Hib disease during the surveillance period the number of Hib cases and 
estimates of vaccination coverage in the study population are needed. No precise vaccine 
coverage data are routinely available in Germany. 
 
The only available representative routine data on vaccination coverage in childhood derive 
from school health examinations. Although these data cover most children at a certain age, 
they have some limitations: they lag 5 to 6 years behind the current vaccination practice and 
do not assess types of vaccine or timing of vaccination. Furthermore, each of the 16 states in 
Germany is responsible for its own school health examination and has different definitions for 
fully immunised children.  
 
Therefore, representative nationwide immunisation surveys were conducted to assess 
precise vaccine information of children applying the random digit dialling method using 
computer assisted telephone interviews (Schulte, 1997). To bridge between telephone 
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interviews on parents with children born between 1 June 1996 and 30 June 1999 (Laubereau 
et al., 2002; Kalies et al., 2004), parents with children born between 1 July 1999 and 30 June 
2003 were chosen for this survey and interviewed between July 2002 and January 2004 
using identical methods (Kalies et al., 2006).  
 
Figure 2 illustrates the different steps of the telephone interviewing process from first call to 
population for analysis: in an initial interview 22,266 households were screened for the 
presence of a child born in the respective birth years (point 0) and asked if they were willing 
to receive a second telephone call concerning questions about the health of their child and 
possible vaccinations (point 1). On request, a letter with the purpose and the names and 
affiliations of the principal investigators of the study was sent to the families. Of all 3,286 
households with children born in the respective years, 2,421 households were willing to 
answer to a second telephone call. Informed consent was obtained from all participating 
parents. 865 households refused participation (point 2); main reasons for non-participation 
were ‘no interest’ (27%), ‘no time to answer’ (20%) and ‘concerns about data safety’ (19%). 
In addition, fourteen households refused participation because their child was not vaccinated, 
although interviewers encouraged them to participate.  
 
In the second telephone call, parents were asked by a team of trained interviewers to provide 
all dates and brand names of vaccinations from the relevant pages of their child’s vaccination 
booklet. If records were unreadable, parents were asked to send a photocopy of the relevant 
pages, to give contact details of their paediatrician and to sign a declaration authorising the 
paediatrician to release vaccination information. If no vaccination booklet was available and 
the child had been vaccinated at least once, parental consent was sought to approach the 
paediatrician for the vaccination information. Additionally, birth date, sex and place of 
residence of the child and socio-economic status of the parents (education, occupation and 
household income) were collected.  
 
Out of all 2,421 households who initially agreed to participate, 262 households could not be 
contacted in the second stage (point 3) due to quality neutral drop outs; main reasons were a 
change of the family’s telephone number in the time between first and second call (48%), no 
child born in the respective year - despite former information - (20%) and no person reached 
at this telephone number within the maximum number of twelve telephone calls (19%).  
 
Out of the 2,421 households who initially agreed to participate, 232 households declined to 
participate in the second stage when contacted (point 4); main reasons were ‘no interest on 
subject of survey’ (18%) and ‘no time’ (15%).  
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Response rates to the telephone interviews were calculated according to international 
standards (Smith et al., 2001): ‘number of completed interviews’ divided by the result of the 
‘number of screened households with children born in the respective years’ minus the 
‘number of households which could not be reached at the second telephone call because of 
reasons unlikely to be related to the exposure of interest’ (change of family’s telephone 
number in the time between first and second telephone call; no person reached at this 
telephone number within a maximum number of twelve telephone calls; child not belonging to 
eligible age group [in contrast to first telephone call’s information]). This corresponds to: point 
5 / ( point 1 – point 3) in figure 2.  
 
Data of the immunisation survey were compared with official data for the German population 
regarding geographical and socio-economic variables. For this purpose, data of the 
‘Mikrozensus’ were used (Federal Statistical Office Germany, 2002): the ‘Mikrozensus’ is 
conducted annually on a representative sample of one percent of the German population. It 
collects data on working life, education as well as social and family life stratified by marital 
status and number and age of children in the respective family. The data of the telephone 
survey were compared with data on families with at least one child under the age of three 
years.  
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Figure 2:  Telephone interviews to assess vaccination coverage of children in Germany. HH = 
number of households 
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6.4 Data analysis 
6.4.1 Incidence rates 
Age-specific annual incidence rates were calculated for the following age groups:  
- 0-2 months 
- 3-11 months  
- 1.0-4.9 years  
- 5.0-9.9 years.  
 
The denominators used for the calculation of the annual incidence rates were extracted from 
the official population data of the Federal Statistical Office Germany (2005). Table 1 shows 
these denominators by year. At the time of this study, data on age groups under one year 
were not available for the year 2004. They were estimated by using 2003 data.  
 
Table 1:  German official population data (‘Statistisches Bundesamt’) used for calculation of 
annual incidence rates  
Age-group  2004 2003 2002 2001 2000 1999 1998 
0-2 months 176,612 * 176,612 179,813 183,939 191,638 193,235 197,441
3-11 months 529,837 * 529,837 539,438 551,816 574,916 579,705 592,325
1.0-4.9 years 2,945,564 3,017,871 3,085,271 3,157,229 3,177,290 3,178,090 3,171,126
5.0-9.9 years 3,974,875 3,984,183 4,005,842 4,017,158 4,073,345 4,255,004 4,417,203
All age groups 7,626,888 7,708,503 7,810,364 7,910,142 8,017,189 8,206,034 8,378,095
* 2004 official data not available at the time of this report. 2003 numbers provided here.  
 
 
6.4.2 Survival analysis for uptake and timing of immunisations 
Uptake and timing of immunisation by age in months was calculated according to the Kaplan-
Meier method. ‘Time of survival’ was defined as the period from birth to receipt of the 
respective dose or series. The inverse survival is the probability of being vaccinated at time t, 
which is the coverage rate at a certain age. 95% confidence intervals (CI) were calculated 
using the Greenwood formula (Cox & Oakes, 1984). The Kaplan-Meier method for vaccine 
uptake is described in detail by Laubereau et al. (2002). Figure 3 demonstrates possible 
interpretations of an inverse Kaplan-Meier curve: this fictive vaccination is recommended at 
age 2 months.  
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Figure 3:  Proportion of children vaccinated with a fictive vaccination by child’s age. Inverse 
Kaplan-Meier curves with 95% confidence intervals. Recommended age-period lies 
between vertical lines. Blue, red and green lines illustrate proportion vaccinated at 24 
months, median age and proportion vaccinated at recommended age, respectively.  
 
 
6.4.3 Adjustments for underreporting and proportion serotyped 
For a proper interpretation of number of cases or changed incidences over time one must be 
sure that the two ESPED systems report the ‘true’ number of invasive Hi and Hib cases in 
Germany. Since identification of all cases can rarely be achieved in any disease monitoring 
system, estimates of completeness and eventual corrections for incompleteness are 
essential. In addition, changed proportions of typed Hi cases - and therefore the possibility to 
detect a type b case - may result in changing numbers of Hib cases reported and should be 
adjusted for.  
 
6.4.3.1 Adjustment for underreporting of Hi cases through the reporting systems 
Approaches to correct for incompleteness of case ascertainment are referred to as capture-
recapture method. An estimate of the ‘true’ number of cases (N) can be calculated based on 
the number of cases ascertained by each single source (here: two sources A and B), the 
number of cases present in both sources (AB), with a correction factor for small samples 
(McCarty et al., 1993):  
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and confidence intervals constructed by  
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with kτ as the respective k-quantile of the standard normal distribution.  
 
An assumption to calculate reliable capture-recapture estimators is that the different sources 
have to be independent of each other. No dependency of these two sources was assumed 
because the two ESPED systems rely on two different reporting systems working 
independent of each other.  
 
6.4.3.2 Adjustment for differences in the proportion of typed cases over time 
The following formula was used to correct for changes in the proportion of Hib isolates typed 
over time (McVernon et al., 2004):  
 
⎥
⎦
⎤
⎢
⎣
⎡
×⎟⎟
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⎞
⎜⎜
⎝
⎛
+= reportsHiuntyped
reportsHitypedall
reportsHibknownreportsHibknownreportsHibadjusted  
 
6.4.4 Vaccine effectiveness 
Before a vaccine is licensed, its efficacy normally had been investigated in randomised 
double-blinded clinical trials. If the efficacy of a vaccine is investigated ‘in the field’, under 
more complex and unpredictable natural conditions this efficacy in the field is called 
effectiveness. Therefore, the term vaccine effectiveness (VE) is used throughout this 
document.   
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6.4.4.1 Theory 
The analytic approach of this vaccine effectiveness study was that of a case-cohort study 
(Prentice, 1986; Barlow et al., 1999) describing a study design which is a mixture between 
case-control and cohort study. Case-cohort studies are of relevance if disease occurrence is 
rare and assessment of vaccine status and other covariables is hard or expensive to collect. 
In a defined population all cases with their vaccination status and interesting covariables are 
assessed; in a subcohort, which is a representative fraction of the whole population, accurate 
information on the same variables is assessed. In contrast to case-control studies a case can 
also be found in the subcohort. This is demonstrated by figure 4.  
 
Cases
Full cohortRepresentative sample of the full cohort
= Subcohort
 
Figure 4:  Schematic description of case-cohort design 
 
 
Vaccine effectiveness is generally measured as 1 minus some measure of relative risk (RR) 
in the vaccinated group compared to the unvaccinated group (Halloran et al., 1997):  
 
RRVE −=1  
 
Analysis of case-cohort design is relatively complex as no standard software exists that 
provides appropriate analyses. Nevertheless, the advantage of case-cohort design over 
other designs is that time until disease outbreak and timing of vaccinations or differing 
immunisation status with repeated vaccinations can be considered.  
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6.4.4.2 Hib vaccine effectiveness 
According to the date of introduction of DTaP-HBV-IPV/Hib combination vaccines (October 
2000) and to the German immunisation schedule (three doses given at the age of 2, 3 and 4 
months, with a booster dose given at the age of ≥ 11 months), cases born from 1 August 
2000 onwards and aged two months or more were considered eligible to have received a 
hexavalent vaccine in the primary series.  
 
Therefore all infants in Germany born between 1 August 2000 and 30 June 2003 were 
defined to be eligible for main calculations of effectiveness of hexavalent vaccines and 
therefore constitute the full cohort. The Lexis diagram in figure 5 displays these at-risk 
periods for the case and cohort children.  
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1
2
3
4
5
9
6
10
7
8
Start of 
ESPEDStart of birth
cohorts included
in subcohort
Last date of case
recruitment
last 
interviewEnd of birth
cohorts included
in subcohort
Introduction of 
hexavalent vaccines
in Germany
 
Figure 5:  Lexis diagram displaying the at-risk periods for cases and sub-cohort members. 
Children within the dark polygon will be eligible for main calculations of hexavalent 
vaccine effectiveness.  
 
Cases with confirmed systemic Hib infections were ascertained by the ESPED-system as 
described in chapter 6.2.2 and contributed to main vaccine effectiveness calculations if born 
between 1 August 2000 and 30 June 2003, aged 2 months or more at disease onset and 
detected by the ESPED system until 31 December 2003. Cases with untyped invasive Hi 
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disease – and therefore potentially belonging to serogroup b – were included as Hib cases in 
sensitivity analysis.  
 
From the full cohort, a representative sub-cohort was randomly sampled in the nationwide 
immunisation survey as described in chapter 6.3 and contributed to main vaccine 
effectiveness calculations if born between 1 August 2000 and 30 June 2003.  
 
Since uptake of vaccine information in the nationwide immunisation survey was assessed 
until January 2004 only, cases contributed to vaccine effectiveness calculations only if 
detected until a comparable date, 31 December 2003.  
 
Hib vaccine effectiveness was assessed for both DTaP-IPV-HB/Hib combination vaccines 
(Hexavac®; Infanrix hexa®) together. In Germany, physicians are free to choose any of the 
licensed vaccines for immunisation of infants and children. Therefore, children can receive a 
mixed schedule with different types of Hib vaccines. Children receiving mixed schedules of 
DTaP-IPV-HB/Hib combination vaccines and other Hib vaccines were not considered for the 
main effectiveness calculations, but considered in sensitivity analysis.  
 
The case-cohort study was analysed using Cox regression as suggested by Barlow (1994) 
and Prentice (1986), and as first applied to vaccine effectiveness studies by Moulton et al. 
(1995). Children in the sub-cohort became at risk at birth or at the start of the surveillance 
period if the latter was later in time. They were censored on the date of their last interview. 
Cases became at risk only on the date of positive Hib culture. It was assumed that no child in 
the sub-cohort later became a case: with an annual incidence of approximately 0.2 / 100,000 
invasive Hib cases in the German population, only 0.005 cases would be expected in the 
sub-cohort. This assumption seems therefore realistic. Age was used as the analysis 
timeline. The vaccine status of subcohort members was defined by the child’s age at each 
dose and was included as a time-dependent covariate. To assess the estimates of vaccine 
effectiveness, two models with mutual exclusive covariates indicating (1) completeness of 
vaccination schedule (receipt of first to second primary series / full primary series / 2nd year 
dose but no full immunisation / full immunisation of DTaP-IPV-HB/Hib combination vaccine) 
and (2) age-eligibility of the vaccination schedule (immunised according to / not according to 
recommended schedule) was used. Figures 6a and 6b visualise the concept of time-
dependent variables for both models. For robust variance estimation an infinitesimal 
jackknife estimator of the influence function variance was used (Barlow, 1994).  
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Case Cohort Design: modelling
Vaccine effectiveness for 1-2 primary, full priming and 2nd year dose and full immunisation
(definition according to STIKO recommendations)
Time-dependent mutually exclusive variables (dummies)
12 months
1-2 primary
full priming
„booster“- but not fully immunised
1-2 primary
full priming
„booster“ – but no full immunisation
1-2 primary
full priming
„booster“ – but not fully immunised
1-2 primary
full priming
„booster“ – but not fully immunised
1-2 primary
full priming
„booster“ – but not fully immunised
1-2 primary
full priming
„booster“ – but not fully immunised
Fully immunised (3 + 1)
Fully immunised (3 + 1)
Fully immunised (3 + 1)
Fully immunised (3 + 1)
Fully immunised (3 + 1)
Fully immunised (3 + 1)
 
Figure 6a:  Example of the changing vaccination status of six children by time (blue line) 
defined by ‘completeness of the vaccination schedule’. Each vertical bar represents a 
Hib vaccination. The time-dependent mutual exclusive variables used in the model (so-
called dummies) are represented by the four red lines below each child. Upward steps 
mark the change from zero to 1 and vice versa at this time in the model.  
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Case Cohort Design: modelling
Vaccine effectiveness for immunisation according to recommended schedule
(definition according to STIKO)
Time-dependent mutually exclusive variables (dummies)
12 months
according
according
6 months 16 months2 months
according
according
according
according
according
 
Figure 6b:  Example of the changing vaccination status of seven children by time (blue line) 
defined by ‘age-eligibility of the vaccination schedule’. Each vertical bar represents a 
Hib vaccination. The time-dependent variable used in the model is represented by the red 
line below each child. Upward steps mark the change from zero to 1 and vice versa at this 
time in the model.  
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6.4.4.3 Sensitivity analysis 
For the sensitivity analysis the effect on vaccine effectiveness was evaluated if  
 (1) children with mixed vaccine schedules (mixture of other DTaP-containing or non-
DTaP containing vaccines with hexavalent vaccines within a child) were included as 
having received hexavalent Hib combination vaccines only,  
(2) cases with untyped invasive Hi disease - and therefore potentially belonging to the 
serotype b group - were included as Hib cases.  
 
For all statistical analysis SAS (SAS Institute, Cary, NC) version 9.1 was used.  
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7 RESULTS 
7.1 Data quality 
7.1.1 ESPED surveillance system 
7.1.1.1 Response rates 
In the years 2001 through 2004, the annual number of Clinical ESPED cards sent out was 
5419, 5339, 5473, and 5544 of which 5301, 5238, 5339, and 5420 cards were returned, 
respectively. Per year, 42, 45, 48, and 35 follow-up questionnaires were sent out to 
paediatricians and 41, 44, 45, and 31 of these questionnaires were returned.  
 
In the years 2001 through 2004, the annual number of Laboratory ESPED cards sent out 
was 3535, 3474, 3502 and 3402 of which 3392, 3311, 3336 and 3280 cards were returned, 
respectively. Per year, 40, 23, 29, 23 follow-up questionnaires were sent out or telephone 
calls were made and 38, 23, 26 and 21 of these questionnaires were returned or answered. 
 
The resulting response rates are high and do not differ from the years before the introduction 
of hexavalent vaccines (Table 2).  
 
Table 2:  Response rates to Clinical and Laboratory ESPED from 1998 to 2004 
Response rate 
Year of surveillance Clinical ESPED 
cards 
Clinical ESPED 
questionnaires 
Laboratory 
ESPED 
cards 
Laboratory 
ESPED 
questionnaires / 
telephone calls 
1998-99 95% 99% 96% * 
2000 98% 100% 100% * 
2001 98% 98% 96% 95% 
2002 98% 98% 95% 100% 
2003 98% 94% 95% 90% 
2004 98% 89% 96% 91% 
*  Laboratory ESPED questionnaires / telephone calls were routinely added in year 2001.  
 
 
There were no substantial differences between response rates of the 16 federal states in 
Germany (‘Bundesländer’) for either Clinical or Laboratory ESPED cards (table 3). Lowest 
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response rates were observed in the city state ‘Hamburg’ for Laboratory ESPED cards in 
2001 (83%) and for Clinical ESPED cards in 2004 (85%).  
 
Table 3:  Response rates of Clinical and Laboratory ESPED cards by German federal states 
(‘Bundesland’) in 2001 through 2004.  
 Response rate 
2001 2002 2003 2004 
‘Bundesland’ Lab 
ESPED 
Clinical 
ESPED
Lab 
ESPED
Clinical 
ESPED
Lab 
ESPED
Clinical 
ESPED 
Lab 
ESPED
Clinical 
ESPED
Baden-Württemberg 97% 99% 96% 100% 93% 98% 98% 99% 
Bayern 97% 100% 95% 100% 97% 98% 92% 98% 
Berlin 97% 92% 94% 97% 88% 92% 96% 100% 
Brandenburg 95% 99% 100% 99% 99% 96% 95% 100% 
Bremen 100% 100% 100% 100% 89% 100% 92% 97% 
Hamburg 83% 97% 87% 100% 92% 94% 99% 85% 
Hessen 100% 94% 98% 99% 93% 100% 91% 100% 
Mecklenburg-Vorpommern 99% 100% 99% 100% 100% 100% 100% 100% 
Niedersachsen 99% 99% 95% 96% 100% 98% 100% 98% 
Nordrhein-Westfalen 94% 96% 91% 97% 94% 98% 96% 96% 
Rheinland-Pfalz 99% 97% 97% 95% 100% 93% 95% 97% 
Saarland 100% 100% 97% 100% 100% 100% 100% 100% 
Sachsen 99% 100% 99% 100% 99% 100% 97% 100% 
Sachsen-Anhalt 88% 100% 89% 100% 88% 99% 99% 100% 
Schleswig-Holstein 86% 86% 94% 86% 87% 86% 98% 86% 
Thüringen 97% 100% 99% 99% 99% 100% 99% 100% 
 
 
7.1.1.2 Completeness of case reporting 
Through both surveillance systems, a total of 51, 39, 63, 50, 42, 41 and 27 cases of invasive 
H. influenzae (Hi) disease were reported annually in 1998 through 2004.  
 
The proportions of reported cases have been consistently lower for Clinical compared to 
Laboratory ESPED for every year of surveillance since 1998 (table 4). However, more 
dramatic manifestations (meningitis, epiglottitis, septic arthritis) of invasive Hi disease are 
more likely to be reported to the Clinical ESPED system. The proportion of these cases 
among all Clinical ESPED cases was 66% in 2001, 62% in 2002, 66% in 2003 and 50% in 
2004 as compared to 49% in 2001, 56% in 2002, 51% in 2003 and 36% in 2004 in 
Laboratory ESPED. Similar findings could be observed in the 1998 to 2000 data on H. 
influenzae surveillance.  
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Table 4:  Number and proportion of detected cases by data source from 1998 to 2004 
Data source 
Clinical ESPED Lab ESPED Year of surveillance 
number % of total number % of total 
Duplicates 
(detected in 
both sources) 
Total N 
cases 
1998 30 59% 45 88% 24 51 
1999 21 54% 32 82% 14 39 
2000 32 51% 50 79% 19 63 
2001 29 58% 49 98% 28 50 
2002 26 62% 39 93% 23 42 
2003 27 66% 39 95% 25 41 
2004 14 52% 22 81% 9 27 
 
 
Applying capture-recapture methodology, the proportion of all ‘true’ Hi cases in German 
children that has been captured by each single source ranged between 38.5% and 64.1% for 
Clinical ESPED and between 59.1% and 96.6% for Laboratory ESPED. Both sources 
together captured 75.7% to 97.4% of Hi cases per year (table 5).  
 
Table 5:  Observed number of cases and estimated completeness of the two ESPED systems 
by year of surveillance using capture-recapture method.  
 1998 1999 2000 2001 2002 2003 2004 
Clinical ESPED 30 21 32 29 26 27 14 
Laboratory ESPED 45 32 50 49 39 39 22 
Duplicates 24 14 19 28 23 25 9 
total number of cases 51 39 63 50 42 41 27 
% captured by both systems 91.1% 82.3% 75.7% 98.6% 95.5% 97.4% 80.6% 
% captured by Clinical ESPED 53.6% 44.3% 38.5% 57.2% 59.1% 64.1% 41.8% 
% captured by Lab ESPED 80.4% 67.5% 60.1% 96.6% 59.1% 92.6% 65.7% 
 
 
7.1.1.3 Proportion of cases typed 
The percentage of untyped cases decreased from 25% of all reported invasive Hi cases in 
1998 to 15% in 2004 (table 6).  
 
In concordance to the increasing proportion of cases typed, serotyping in the national 
consulting laboratory of Hi increased from 1998 to 2004: 55% of all reported cases were 
typed in the national consulting laboratory in 1998, 58% in 1999, 63% in 2000, 70% in 2001, 
74% in 2002, 73% in 2003 and 70% in 2004.  
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Table 6: Total number of cases and proportion of untyped cases from 1998 to 2004 
Year of 
surveillance N Cases Total untyped 
1998 51 13 (25%) 
1999 39 11 (28%) 
2000 63 13 (21%) 
2001 50 10 (20%) 
2002 42  8 (19%) 
2003 41  7 (17%) 
2004 27  4 (15%) 
 
 
Adjustments to correct for changes in the proportion of Hib isolates typed over time (see 
chapter 6.4.3.2) are presented in chapter 7.3.1.  
 
7.1.1.4 Serotyping: concordance between local and reference laboratories 
Of all 131 cases serotyped in 2001 through 2004, 77 were serotyped in both, local 
laboratories and the national consulting laboratory for Hi in Mainz, 19 were serotyped in local 
laboratories only and 35 in the national consulting laboratory only. Of the 77 specimens 
typed by both laboratories, eight specimens presented discordant serotype results. Of these, 
seven specimens were typed as type b in the local laboratory but as non-type b in the 
reference laboratory (5 as a-f negative, 1 as type f, 1 as type a) and one was typed as non-
type b (a-f negative) in local laboratories but as type b in the reference laboratory. According 
to chapter 6.2.2.4, these eight specimens were classified according to the results of the 
national consulting laboratory for Hi (table 7).  
 
Table 7:  Concordance of typing results between local laboratories and the reference 
laboratory in 2001 through 2004. The eight cases with discordant typing results are 
marked in green.  
Reference laboratory Local laboratories Type b Non-type b Untyped 
Type b 28 7 15 
Non-type b 1 41 4 
Untyped 8 27 29 
Final typing results 37 75 48 
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7.1.2 National immunisation survey 
7.1.2.1 Response rates and data validity 
Out of all 3286 contacted households with children in the respective birth cohorts, 262 
households could not be reached in the second stage of the interview. In total, 1927 
houshoulds with 2011 children born between 1 July 1999 and 30 June 2003 were 
interviewed. The resulting response rate was 63%. For analyses 20 children with no 
vaccination booklet available and 19 children with implausible immunisation data (too many 
vaccinations, no vaccination date, implausible dates) were excluded (figure 2; point 6). For 
the remaining 1972 children median age at interview was 26.0 months. The number of 
telephone interviews and child’s age at interview by birth year of the respective child is 
shown in table 8.  
 
Table 8:  Number of telephone interviews and child’s age at interview by birth year of the 
child.  
Year of birth Age at interview 1999 2000 2001 2002 2003 
0-<6 months - - - 2 - 
6-<12 months - - 2 4 65 
1-<2 years - 1 91 451 3 
>= 2 years 320 577 453 3 - 
total 320 578 546 460 68 
Median (month) 
(10th-90th perc) 
38.6 
(33.4-52.4) 
30.9  
(24.7-43.9) 
25.0  
(19.5-32.5) 
12.8  
(12.3-21.4) 
6.5  
(6.2-11.6) 
Range (min-max) 30.6-54.4 22.7-48.0 9.1-36.4 1.2-24.5 6.1-12.3 
 
 
For the description of the immunisation status in German children (chapter 7.2.2) and 
vaccine effectiveness calculations (chapter 7.5), data of all 1303 children born from 1 August 
2000 onwards will be presented as these children belong to the birth cohorts which could 
have received a hexavalent vaccine in the primary series.   
 
7.1.2.2 Representativeness 
Comparisons with data of the ‘Mikrozensus’ revealed that the sampled telephone interviews 
are representative for age-eligible children in Germany according to geographical and social 
distributions (figures 7a-c). Children from households with higher income are slightly over-
represented (figure 7d).  
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e. by household net income 
Figure 7:  Comparison of sociodemographic characteristics between families taking part in 
the national immunisation survey and official data of the Statistical Office in 
Germany (‘Mikrozensus’).  
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7.2 General description of the data 
7.2.1 H. influenzae cases 2001-2004 
7.2.1.1 Seasonal distribution 
Out of all 160 invasive Hi cases in children under 10 year of age detected in the ESPED 
surveillance system from 2001 through 2004, the majority of cases were reported in autumn 
and winter: most cases occurred in December, January and October (22, 19, 19 cases 
each). In the remaining months, 6-16 cases were reported every month (table 9).  
 
Table 9:  Number of invasive H. influenzae cases reported by month in 2001 through 2004.  
Month N Cases 
January 19 
February 12 
March 16 
April 11 
May 11 
June 14 
July 6 
August 11 
September 6 
October 19 
November 13 
December 22 
 
 
7.2.1.2 Distribution by age, sex and nationality 
Of the 160 reported invasive Hi cases 
- 25 cases (16%) occurred in children aged 0 to 2 months,   
- 42 cases (26%) occurred in children aged 3 to 11 months, 
- 74 cases (46%) occurred in children aged 12 months to 4 years and  
- 19 cases (12%) occurred in children aged 5 to 10 years.  
 
There were 96 cases of invasive Hi disease in boys and 64 cases in girls (60% vs. 40%).  
 
Information about nationality of the child was available for 153 of the 160 cases. Of these, 
78% had a German and 22% a non-German nationality; most children with non-German 
nationality (n=34) were from other European countries (n=14) or from Turkey (n=6).   
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7.2.1.3 Clinical description 
Haemophilus influenzae pathogens were isolated 
- in the cerebrospinal fluid for 29 cases (18%), 
- in blood for 80 cases (50%), 
- in both blood and cerebrospinal fluid for 43 cases (27%), 
- in peritoneal fluid for 3 cases (2%) and  
- in other physiologically sterile material for 5 cases (3%).  
 
Information about the primary diagnosis was available for all 160 cases. The most common 
clinical presentation of invasive Hi infection in children was meningitis, constituting almost 
one half of all reports (46%). Table 10 shows the distribution of all primary diagnoses by age 
group. The category ‘other’ includes 6 cases of epiglottitis. The most common clinical 
presentation in the very young (0-2 months) was septicaemia (40%) whereas this changed to 
meningitis (42-52%) in the older age groups.  
 
Table 10:  Distribution of invasive H. influenzae disease by primary diagnosis and age group 
in 2001 through 2004.  
Age groups Primary 
diagnosis 0 - 2 months N (%) 
3 - 11 months
N (%) 
1.0 - 4.9 years
N (%) 
5.0 - 9.9 years 
N (%) 
Total 
N (%) 
Meningitis 7 (28%) 22 (52%) 36 (49%) 8 (42%) 73 (46%) 
Pneumonia 7 (28%) 6 (14%) 14 (19%) 2 (11%) 29 (18%) 
Septicaemia 10 (40%) 6 (14%) 8 (11%) 3 (16%) 27 (17%) 
Other 1 (4%) 8 (19%) 16 (22%) 6 (31%) 31 (19%) 
Total 25 42 74 19 160 
 
 
The clinical outcome of Hi disease was known for 138 of the 160 cases; of the 138 cases  
- 9 children (6%) died,  
- 121 children (88%) recovered from the acute infection without any obvious sequelae 
and 
- 8 (5%) had serious sequelae (e.g. hygroma, hydrocephalus). 
 
Information on underlying medical conditions was reported for 153 of all 160 children. Fifteen 
of these children (10%) were born prematurely before 37 weeks gestation (median gestation: 
32 weeks; range 25-36 weeks). Three children had Down’s syndrome (2%) and four children 
had immunodeficiency or received immunosuppressive therapy (3%). For 32 children (20%) 
other possible clinical risk factors for Hi infection were reported (malignancies, other 
Haemophilus influenzae type b – Epidemiology and Vaccine Effectiveness in Germany H. Kalies 
 
   37
syndromes, severe injuries). Some children had more than one risk factor; when combined, 
44 children (29%) had at least one possible clinical risk factor.  
 
7.2.1.4 Serotypes 
Serotyping was performed in 131 of the 160 (82%) cases reported from 2001 through 2004. 
Overall 52 cases were determined to be type b and 79 to be non-type b. Of the 79 non-type b 
cases, 15 were capsulated, 60 were non-capsulated (a-f negative) and 4 cases were not 
further specified. Of the 15 capsulated non-b cases, 13 were type f, 1 was type e, and 1 was 
type a. Whereas type b was predominantly a cause of serious infections in the age group 3-
11 months (55%), all other age groups were dominated by non-type b infections (table 11).  
 
Table 11:  Distribution of invasive H. influenzae disease by serotype and age group in 2001 
through 2004 
Age groups 
Serotype 0-2 months 
N (%) 
3-11 months 
N (%) 
1.0-4.9 years 
N (%) 
5.0-9.9 years 
N (%) 
Total 
N (%) 
Type b 4 (16%) 23 (55%) 23 (31%) 2 (11%) 52 (33%) 
Non-type b 16 (64%) 13 (31%) 37 (50%) 13 (68%) 79 (49%) 
 capsulated 0 5 8 2 15 
 non-capsulated 16 7 26 11 60 
 not specified 0 1 3 0 4 
Untyped 5 (20%) 6 (14%) 14 (19%) 4 (21%) 29 (18%) 
Total 25 42 74 19 160 
 
 
Almost one half of all meningitis cases were due to type b infections, whereas children with a 
clinical presentation of pneumonia or septicaemia were predominantly infected by non-
capsulated Hi bacteria (table 12).  
 
Table 12:  Distribution of invasive H. influenzae disease by serotype and primary diagnosis in 
2001 through 2004 
Primary diagnosis 
Serotype Meningitis 
N (%) 
Pneumonia 
N (%) 
Septicaemia 
N (%) 
Other 
N (%) 
Total 
N (%) 
Type b 34 (47%) 4 (14%) 3 (11%) 11 (35%) 52 (33%) 
Non-type b 30 (41%) 17 (59%) 19 (70%) 13 (42%) 79 (49%) 
 capsulated 10 2 1 2 15 
 non-capsulated 19 14 17 10 60 
 not specified 1 1 1 1 4 
Untyped 9 (12%) 8 (28%) 5 (19%) 7 (23%) 29 (18%) 
Total 73 29 27 31 160 
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7.2.1.5 Vaccination status 
Vaccination status was reported in 156 of the 160 (98%) cases reported from 2001 through 
2004. Twenty-one of all 52 (40%) children with known type b disease had been vaccinated at 
least once before disease onset in contrary to 56 of all 79 (71%) children with non-type b 
disease. There were no fatal cases occurring in vaccinated Hib cases. Figure 8 summarises 
these results.  
 
Figure 8:  Description of vaccination status by serotype and outcome of all invasive H. 
influenzae cases reported in the German ESPED surveillance system in the years 
2001 through 2004 
  Non-type b Serotype  Type b  Untyped capsulated uncapsulated  not specified
         
  52  29 15 60  4 
         
Vaccination 
Status*  V NV UK  V NV UK V NV UK V NV UK  V NV UK
                   
  21 31 0  13 12 4 13 2 0 39 21 0  4 0 0 
                   
Outcome=death  0 3 0  1 2 0 1 0 0 0 2 0  0 0 0 
*:  V = vaccinated; NV = not vaccinated; UK = vaccination unknown 
 
 
Of the 21 vaccinated Hib cases detected in the ESPED surveillance system from 2001 
through 2004, seven children were vaccinated with 4 Hib doses, another seven children were 
vaccinated with 3 Hib doses, two children were vaccinated with 2 Hib doses and four children 
were vaccinated with one dose of a Hib containing vaccine before disease onset. For one 
child numbers of Hib containing vaccines given was unclear. Hexavalent vaccines were 
involved in 12 of the 21 children. Of these, four children received one dose of a hexavalent 
Hib vaccine, two children received 2 doses of a hexavalent Hib vaccine, five children 
received 3 doses of a hexavalent Hib vaccine and one child received the last of four Hib 
doses as a hexavalent Hib vaccine before disease onset. A detailed description of the 21 
vaccinated cases with invasive Hib disease is shown in table 13. 
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Table 13:  Vaccination history of the H. influenzae type b cases who received any Hib-
containing vaccine. Age at disease onset and age at vaccination in months. 
vaccination history 
vaccination 1 vaccination 2 vaccination 3 vaccination 4 case vaccine failure* 
age at 
disease 
onset 
N  
vaccination 
age vaccine age vaccine age vaccine age vaccine 
11/01 pr+bo 28 4 3 5-valent 5 5-valent 7 5-valent 13 5-valent 
32/01 incompl pr 6 1 5 hexavalent - - - - - - 
36/01 pr+bo 38 4 3 4-valent 4 5-valent 5 5-valent 15 5-valent 
48/01 pr+bo 41 4 4 5-valent 5 5-valent 6 5-valent 13 Hib mono 
57/01 pr 17 4 4 5-valent 6 5-valent 6 5-valent 8 5-valent 
2/02 pr 12 3 2 hexavalent 4 hexavalent 6 hexavalent - - 
27/02 pr+bo 25 4 2 5-valent 3 5-valent 4 5-valent 12 5-valent 
39/02 pr+bo 48 4 4 4-valent 5 4-valent 6 4-valent 12 4-valent 
2/03 pr 17 3 3 hexavalent 5 hexavalent 7 hexavalent - - 
6/03 incompl pr 8 1 6 hexavalent - - - - - - 
25/03 incompl pr 4 1 3 hexavalent - - - - - - 
32/03 2nd y dose 81 3 5 5-valent 7 5-valent 12 5-valent - - 
34/03 pr+bo 40 4 2 4-valent 3 4-valent 4 4-valent 20 hexavalent 
36/03 incompl pr 4 1 3 hexavalent - - - - - - 
39/03 pr 7 3 2 hexavalent 3 hexavalent 4 hexavalent - - 
44/03 pr 23 3 4 hexavalent 5 hexavalent 8 hexavalent - - 
45/03 incompl pr 6 2 3 hexavalent 4 hexavalent - - - - 
46/03 pr 17 3 3 hexavalent 5 hexavalent 8 hexavalent - - 
9/04 unclear 25 unknown       - - 
10/04 incompl pr 4 2 2 hexavalent 3 hexavalent - - - - 
29/04 pr 49 3 4 5-valent 5 5-valent 6 5-valent - - 
* incompl pr: vaccine failure of the incomplete primary schedule; pr: vaccine failure of the complete primary schedule; pr+bo: 
vaccine failure of the primary and booster regimen; 2nd y dose: vaccine failure of a dose given after the age of 11 months.   
 
 
Median age at disease onset differed between vaccinated and unvaccinated cases with 
invasive Hib disease: 17.0 months (minimum: 4.0; maximum: 81.0) vs. 9.0 months 
(minimum: 1.0; maximum: 104.0). There were more possible clinical risk factors for Hib 
infection present in vaccinated compared to unvaccinated children (19.0% vs. 12.9%). 
Differences in the clinical presentation were marginal (vaccinated Hib cases: 62% meningitis, 
26% other focus, 7% no focus; unvaccinated Hib cases: 68% meningitis, 33% other focus, 
5% no focus).  
 
7.2.2 Immunisation status of children in the German population 
7.2.2.1 Hib vaccine coverage 
In the national immunisation survey, a total of 1303 valid interviews were realised on children 
born between 1 August 2000 and 30 June 2003. Figure 9a-d displays the time course of 
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completion of the first dose, full primary series, the 2nd year dose and the full immunisation 
against Hib for all these children (definitions for these categories are provided in chapter 
6.1.2).  
 
Figure 9a shows that 50% of all children received their first Hib vaccination at the age of 3.4 
months. At the age of 1 year 91.9% of all children have received at least one Hib vaccination.  
At the end of the recommended age for the first dose (2.9 months) only 28.7% received the 
respective dose.  
 
 
Figure 9a:  Hib vaccine coverage in Germany: Proportion of children vaccinated with the first 
Hib dose by child’s age. German national immunisation survey on birth cohorts 1 August 
2000 through 30 June 2003 (N=1303). Inverse Kaplan-Meier curves with 95% confidence 
interval. Recommended age-period lays between vertical lines.  
 
 
Figure 9b shows that completion of the primary series is only achieved by 80% of the 
children; at the end of the recommended age (4.9 months) only 16.6% of all children have 
received the complete primary series. Coverage of 75% is reached by the age of 9.1 months.  
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Figure 9b:  Hib vaccine coverage in Germany: Proportion of children vaccinated with the full 
primary schedule by child’s age. German national immunisation survey on birth cohorts 
1 August 2000 through 30 June 2003 (N=1303). Inverse Kaplan-Meier curves with 95% 
confidence interval. Recommended age-period lays between vertical lines.  
 
Figure 9c shows that completion of the 2nd year dose is only achieved by 5.5% of the children 
at the age of 1 year and by 78.8% at the age of 2 years; at the end of the recommended age 
(14.9 months) only 37.5% were adequately vaccinated. Coverage of 50% and 75% is 
reached by the age of 16.6 months and 23.1 months, respectively.  
 
 
Figure 9c:  Hib vaccine coverage in Germany: Proportion of children with 2nd year dose by 
child’s age. Inverse Kaplan-Meier curves with 95% confidence interval. German national 
immunisation survey on birth cohorts 1 August 2000 through 30 June 2003 (N=1303). 
Recommended age-period lays between vertical lines.  
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Figure 9d shows that completion of the full immunisation schedule is only achieved by 64.1% 
at the age of 2 years; a coverage of 50% is reached by the age of 18.5 and a coverage of 
75% or more is never reached.  
 
 
Figure 9d:  Hib vaccine coverage in Germany: Proportion of children fully immunised by child’s 
age. Inverse Kaplan-Meier curves with 95% confidence interval. German national 
immunisation survey on birth cohorts 1 August 2000 through 30 June 2003 (N=1303). 
Recommended age-period lays between vertical lines.  
 
 
Table 14 summarises the results of figures 9a-d for age at defined coverage levels for Hib 
vaccination and coverage at defined ages.  
 
Table 14:  Age of children at defined coverage levels for Hib vaccination and Hib vaccination 
coverage at one / two years of age and at recommended age as calculated by 
Kaplan-Meier method (95% confidence intervals). German national immunisation survey 
on birth cohorts 1 August 2000 through 30 June 2003 (N=1303). 
Age (months) at coverage of Proportion (%) vaccinated at  
25% 50% =median age 75% age 1 year age 2 years 
recommended 
age* 
First dose 2.8 (2.6-2.9) 
3.4 
(3.4-3.5) 
4.1 
(4.0-4.2) 
91.9 
(90.3-93.3) 
95.3 
(94.0-96.5) 
28.7 
(26.3-31.3) 
Full priming# 5.4 (5.3-5.5) 
6.5 
(6.3-6.6) 
9.1 
(8.4-10.1) 
80.0 
(77.7-82.1) - 
16.6 
(14.7-18.7) 
2nd year dose# 13.7 (13.4-13.9) 
16.6 
(16.2-17.0) 
23.1 
(21.9-23.9) 
5.5 
(4.4-6.9) 
78.8 
(75.9-81.6) 
37.5 
(34.6-40.6) 
Full immunisation# 14.1 (13.8-14.4) 
18.5 
(17.7-19.4) not reached 
5.5 
(4.4-6.9) 
64.1 
(60.8-67.3) 
31.6 
(28.8-34.5) 
#  see definitions in methods section 
* proportion of children vaccinated within the age-frame recommended by the STIKO: at least one dose at <3 months, the 
full primary series at <5 months and the 2nd year dose/full immunisation at <15 months. 
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7.2.2.2 Use of hexavalent vaccines 
Of all 1303 children with valid data, 72 (5.5%) had never been vaccinated against Hib at the 
age of the interview, 890 (68.3%) had received DTaP-IPV-HB/Hib combination vaccines only, 
158 (12.1%) had received DTaP-(IPV)/Hib combination vaccines only, 23 (1.8%) had 
received Hib vaccines without acellular pertussis component only, 158 (12.1%) had received 
mixed schedules of Hib vaccines and two children (0.2%) had received at least one vaccine 
where brand name was not reported.  
 
Of those 158 children receiving mixed schedules of Hib vaccines, 151 (95.6%) had received 
mixed schedules of DTaP-IPV-HB/Hib combination vaccines and other Hib vaccines.  
 
The use of hexavalent vaccines per child increased with the child’s year of birth from 47.9% 
in 2000 to 76.6% in 2003, while the use of 4- and 5-valent Hib containing vaccines 
decreased from  24.9% in 2000 to 17.2% in 2003 (Table 15).  
 
Table 15:  Distribution of type of vaccine per child for children ever vaccinated with Hib 
containing vaccine by birth year. German national immunisation survey on birth cohorts 
1 August 2000 through 30 June 2003 (N=1231). 
Year of birth Proportion ever vaccinated with … 2000 2001 2002 2003 
Hib vaccines without Pa 2.8 2.9 0.5 0.0 
DTaP-(IPV)/Hib 24.9 11.1 8.2 17.2 
DTaP-IPV-HB/Hib 47.9 71.5 85.1 76.6 
Mixed types* 24.4 14.4 6.1 6.3 
Unknown types 0.0 0.2 0.2 0.0 
Total number of children vaccinated 229 522 428 64 
* Children receiving mixed schedules of the above categories of vaccines (including mixtures of DTaP-IPV-HB/Hib) 
 
 
7.2.2.3 Timeliness of hexavalent vaccine uptake 
Table 16 shows the median age of children vaccinated with hexavalent vaccines only in 
comparison to the recommended schedule. The first two doses were administered with a 
delay of approximately 0.5-1.5 months compared with national recommendations. The third 
dose was administered with a median age of 6.1 months; this is 1.2 months later than the 
upper limit of the national recommendations. The median age at which the fourth dose was 
administered was 14.3; this is near the upper limit of the national recommendations.  
 
According to the definitions given in the methods section, the median age at full priming was 
6.0 months, at 2nd year dose 14.4 months and at full immunisation (fully primed + booster) 
14.3 months.  
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Table 16:  Median age of children vaccinated with hexavalent vaccines in comparison to 
national recommendations in Germany (Kaplan-Meier estimates). German national 
immunisation survey on birth cohorts 1 August 2000 through 30 June 2003. 
 
Number 
vaccinated with 
respective dose 
Median age (95% 
CI) at vaccination 
(month) 
Range of age 
(months) 
National 
recommendation 
(month) 
1st dose  890 3.3 (3.2 - 3.4) 1.0 - 25.0 2.0 - 2.9 
2nd dose 865 4.6 (4.5 - 4.7) 2.0 - 23.9 3.0 - 3.9 
3rd dose 829 6.1 (5.9 - 6.2) 2.8 - 26.5 4.0 - 4.9 
4th dose 477 14.3 (13.9 - 14.7) 4.0 - 30.4 11.0 - 14.9 
Full priming 779 6.0 (5.8 - 6.1) 2.8 - 12.0 4.0 - 4.9 
2nd year dose 516 14.4 (14.1 - 14.8) 11.0 - 30.4 11.0 - 14.9 
Full immunisation (3+1) 446 14.3 (13.9 - 14.6) 11.0 - 30.4 11.0 - 14.9 
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7.3 Annual numbers of Hib cases and vaccine failures before 
and after licensure of hexavalent vaccines (Objective 1) 
7.3.1 Annual numbers of Hib cases 
In Clinical ESPED only, data on invasive H. influenzae cases were available from year 1993 
onwards, with a gap in the years 1996 and 1997 where no data were collected (figure 10). 
The total number of Hi cases detected by Clinical ESPED decreased drastically by the factor 
8, from 120 cases in 1993 to 14 cases in 2004. This decrease is not as obvious for Hib 
cases: they fluctuated from 15 cases in 1993, 29 in 1994 to 7 in 1999, 15 in 2000 and one in 
2004. Here, the proportion of untyped cases – which probably could belong to type b cases – 
has to be taken into account for proper interpretation.  
 
 
Figure 10:  Annual number of H. influenzae cases by serotype detected in one surveillance 
system (Clinical ESPED) since 1993. In 1996 and 1997 no data on H. influenzae cases 
were collected. At the end of 2000 hexavalent vaccines were introduced on the German 
market.  
 
 
In both surveillance systems together (Clinical and Laboratory ESPED), the total number of 
detected Hi cases decreased from 51 cases in 1998 to 39 in 1999, rose again to 63 cases in 
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2000 and decreased to 27 cases in 2004 (figure 11). The number of Hib cases fluctuated 
between 28 cases in 1998 and 4 cases in 2004.  
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Figure 11:  Annual number of H. influenzae cases by serotype detected in both surveillance 
systems (Clinical and Laboratory ESPED) since 1998. At the end of 2000 hexavalent 
vaccines were introduced on the German market. 
 
 
Correcting these numbers for incompleteness of the surveillance system using capture-
recapture estimates, the same pattern was found (table 17): highest estimated number of Hi 
cases in 2000 (83 cases), lowest in 2004 (34 cases); highest estimated number of Hib cases 
in 1998 (30 cases), lowest in 2004 (7 cases). In 2004, the number of estimated ‘true’ number 
of Hib cases nearly doubled using capture-recapture method compared to reported numbers 
as shown in figure 11.  
 
Table 17:  Estimated number of H. influenzae cases by year of surveillance and serotype 
using capture-recapture method.  
Estimated number of cases 
by capture-recapture 
method (95% CI) 
1998 1999 2000 2001 2002 2003 2004 
All H. influenzae 56 (50-63) 
47 
(38-57) 
83 
(66-101) 
51 
(49-53) 
44 
(40-48) 
42 
(40-45) 
34 
(25-42) 
 Type b 30 (26-33) 
15 
(12-18) 
23* 
 
18 
(16-19) 
12 
(11-14) 
19 
(19-20) 
7 
(0-14) 
 Non type b 10*  
16 
(13-18) 
27* 
 
23* 
 
22* 
 
15* 
 
21 
(17-25) 
* Here, confidence intervals could not be calculated since all cases detected in one source were also present in the 
second source and therefore variance equates zero (see formula chapter 6.4.3.1).  
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When adjusting Hib cases for changes in the proportion of Hib isolates typed over time (see 
chapter 6.4.3.2), the above described fluctuation in Hib cases was more pronounced. 
Numbers decreased from 38 cases in 1998 to 5 cases in 2004, with intermediate peaks in 
2000 (29 cases) and 2003 (23 cases) in all age groups. The overall decrease in Hib cases 
was mainly due to the age group 12 months to 4.9 years, the fluctuation mainly due to the 
age group 3-11 months (table 18).  
 
Table 18:  Number of Hib cases by year of surveillance and age at disease onset adjusted for 
differences in the proportion of typed cases over time.  
 1998 1999 2000 2001 2002 2003 2004 
All age groups 38 20 29 21 15 23 5 
 0-2 months 0 2 4  3 2 1 0
 3-11 months 7 1 10 8 5 11 3
 12 months – 4.9 years 25 13 12 8 8 10 2
 5.0 – 9.9 years 4 4 2 2 0 1 0
 
 
Since the introduction of hexavalent vaccines at the end of 2000, no increase of invasive Hib 
cases in children could be detected in Germany.  
 
7.3.2 Vaccine failures 
Of all 117 invasive Hib cases detected in both surveillance systems since 1998, 52 were 
vaccinated at least once with a Hib vaccine, 64 were not vaccinated and for one case 
vaccination status was unknown. The annual distribution of vaccinated and unvaccinated Hib 
cases is shown in figure 12.  
 
Haemophilus influenzae type b – Epidemiology and Vaccine Effectiveness in Germany H. Kalies 
 
   48 
 
14
7 10 3
10
14
7
12
12
9
9
1
10
14
27
23
22
15
19
13
11
13
10
8 7
5
5 3
1
0
10
20
30
40
50
60
70
1998 1999 2000 2001 2002 2003 2004
year of surveillance
N
um
be
r o
f C
as
es not typed
non type b
type b - unknow n vaccination status
type b - unvaccinated
type b - vaccinated
 
Figure 12:  Annual number of H. influenzae cases by serotype and vaccination status detected 
in both surveillance systems (Clinical and Laboratory ESPED) since 1998. At the end 
of 2000 hexavalent vaccines were introduced on the German market. 
 
 
The proportion of vaccinated Hib cases among all Hib cases was 50% in 1998, 50% in 1999, 
45% in 2000, 29% in 2001, 25% in 2002, 52% in 2003 and 75% in 2004.  
 
Of the 64 unvaccinated Hib cases detected since 1998, 59 were old enough to have received 
at least one shot of a Hib vaccine before disease onset if German vaccination 
recommendations would have been followed. Of the 52 vaccinated Hib cases, exact 
numbers of Hib vaccine doses given and age at receipt of Hib vaccines was known for 49 
cases. Of these, 14 received incomplete priming, 19 complete priming, 10 full immunisation 
and 6 the 2nd year dose. Twenty-two of the 49 cases (44%) were not vaccinated according to 
German vaccination recommendations (see definition of ‘age-eligibility of vaccination 
schedule’, chapter 6.1.2); four additional cases immunised with an incomplete primary series 
could have received at least one additional shot of a Hib vaccine before disease onset if the 
exact timing of vaccination recommendations would have been considered.  
 
Figure 13 shows the number of Hib cases by completeness of vaccination schedule and 
compliance with recommendations of the German Vaccine Advisory Board (STIKO).  
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Figure 13:  Number of Hib cases in both surveillance systems since 1998 (n=117) by 
completeness of vaccination schedule and compliance with the timing of the 
recommendations of the German Vaccine Advisory Board (STIKO). Invasive Hib 
cases marked in orange could have received more Hib vaccine doses before disease 
onset if vaccinated according to recommendations.  
 
 
According to the definition of ‘age-eligibility of the vaccination schedule’ (chapter 6.1.2) - 
which is less stringent than the one described in figure 13 - five of the 14 Hib cases 
immunised with an incomplete primary series were ‘immunised according to’ and nine ‘not 
immunised according to’ the recommendations.  
 
Of all vaccinated Hib cases, 12 had been vaccinated with at least one dose of a hexavalent 
vaccine. For these cases, number of Hib vaccine doses given and age at receipt of Hib 
vaccines is described in table 13 (chapter 7.2.1.5). One of these cases was detected in 2001, 
2002 and 2004 each and 9 were detected in 2003.  
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7.4 Annual incidence rates of H. influenzae cases before and 
after licensure of hexavalent vaccines (Objective 2) 
7.4.1 H. influenzae 
Overall annual incidence rates of invasive H. influenzae disease were relatively constant 
throughout the years 1998 to 2004 (table 19). The highest incidence rates were found in the 
0-2 month age group (7.3 and 5.4 per 100,000 in 2000 and 2001, respectively) and in the 3-
11 month age group (2.6, 2.7 and 2.6 per 100,000 in 2000, 2001 and 2003, respectively). 
The increase in incidence was small, all confidence intervals overlapped and there was no 
evidence for an increasing trend.  
 
Table 19:  Age-specific annual incidence rates per 100,000 (95% CI) of invasive H. influenzae 
disease from 1998 to 2004 
0-2 months 3-11 months 1.0 – 4.9 years 5.0 – 9.9 years total year 
N incidence N incidence N incidence N incidence N incidence 
1998 6 3.0 (1.1-6.6) 8 1.4 (0.6-2.7) 31 1.0 (0.7-1.4) 6 0.1 (0.0-0.3) 51 0.6 (0.5-0.8) 
1999 9 4.7 (2.1-8.8) 3 0.5 (0.1-1.5) 23 0.7 (0.5-1.1) 4 0.1 (0.0-0.2) 39 0.5 (0.3-0.6) 
2000 14 7.3 (4.0-12.3) 15 2.6 (1.5-4.3) 22 0.7 (0.4-1.0) 12 0.3 (0.2-0.5) 63 0.8 (0.6-1.0) 
2001 10 5.4 (2.6-10.0) 15 2.7 (1.5-4.5) 18 0.6 (0.3-0.9) 7 0.2 (0.1-0.4) 50 0.6 (0.5-0.8) 
2002 5 2.8 (0.9-6.5) 8 1.5 (0.6-2.9) 24 0.8 (0.5-1.2) 5 0.1 (0.0-0.3) 42 0.5 (0.4-0.7) 
2003 4 2.3 (0.6-5.8) 14 2.6 (1.4-4.4) 19 0.6 (0.4-1.0) 4 0.1 (0.0-0.3) 41 0.5 (0.4-0.7) 
2004 6 3.4 (1.2-7.4) 5 0.9 (0.3-2.2) 13 0.4 (0.2-0.8) 3 0.1 (0.0-0.2) 27 0.4 (0.2-0.5) 
 
 
7.4.2 H. influenzae type b 
The same pattern was found when considering the annual incidences of invasive type b 
H. influenzae disease irrespective of the vaccination status (table 20). No substantial change 
- or even a decrease - was observed in incidences for children 1.0-4.9 and 5.0-9.9 years old 
but a possible increase in type b infection was seen among children younger than one year 
in 2000 and 2001. Again, incidence returned to previous levels in 2002, rose again in 2003 
and fall in 2004. However, numbers were very small and all confidence intervals overlapped. 
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Table 20:  Age-specific annual incidence rates per 100,000 (95% CI) of type b invasive 
H. influenzae disease from 1998 to 2004 
0-2 months 3-11 months 1.0 – 4.9 years 5.0 – 9.9 years total year 
N incidence N incidence N incidence N incidence N incidence 
1998 0 0.0 (0.0-1.9) 5 0.8 (0.3-2.0) 20 0.6 (0.4-1.0) 3 0.1 (0.0-0.2) 28 0.3 (0.2-0.5) 
1999 1 0.5 (0.0-2.9) 1 0.2 (0.0-1.0) 9 0.3 (0.1-0.5) 3 0.1 (0.0-0.2) 14 0.2 (0.1-0.3) 
2000 2 1.0 (0.1-3.8) 8 1.4 (0.6-2.7) 11 0.3 (0.2-0.6) 2 0.0 (0.0-0.2) 23 0.3 (0.2-0.4) 
2001 2 1.1 (0.1-3.9) 7 1.3 (0.5-2.6) 7 0.2 (0.1-0.5) 1 0.0 (0.0-0.1) 17 0.2 (0.1-0.3) 
2002 1 0.6 (0.0-3.1) 5 0.9 (0.3-2.2) 6 0.2 (0.1-0.4) 0 0.0 (0.0-0.1) 12 0.2 (0.1-0.3) 
2003 1 0.6 (0.0-3.2) 9 1.7 (0.8-3.2) 8 0.3 (0.1-0.5) 1 0.0 (0.0-0.1) 19 0.2 (0.1-0.4) 
2004 0 0.0 (0.0-2.1) 2 0.4 (0.0-1.4) 2 0.1 (0.0-0.2) 0 0.0 (0.0-0.1) 4 0.1 (0.0-0.1) 
 
 
Annual incidences of vaccinated Hib cases were very low and did not show substantial 
changes over the years – with the exception of the years 2000 and 2003 (table 21): 
incidences for children 3-11 months old rose to 0.7 and 0.9 per 100,000 in 2000 and 2003, 
respectively. But again, numbers are very small and all confidence intervals overlap. 
 
Table 21:  Age-specific annual incidence rates per 100,000 (95% CI) of vaccinated type b 
invasive H. influenzae disease from 1998 to 2003 
0-2 months 3-11 months 1.0 – 4.9 years 5.0 – 9.9 years total year 
N incidence N incidence N incidence N incidence N incidence 
1998 0 0.0 (0.0-1.9) 1 0.2 (0.0-0.9) 12 0.4 (0.2-0.7) 1 0.0 (0.0-0.1) 14 0.2 (0.1-0.3) 
1999 0 0.0 (0.0-1.9) 0 0.0 (0.0-0.6) 5 0.2 (0.1-0.4) 2 0.0 (0.0-0.2) 7 0.1 (0.0-0.2) 
2000 0 0.0 (0.0-1.9) 4 0.7 (0.2-1.8) 5 0.2 (0.1-0.4) 1 0.0 (0.0-0.1) 10 0.1 (0.1-0.2) 
2001 0 0.0 (0.0-2.0) 1 0.2 (0.0-1.0) 4 0.1 (0.0-0.3) 0 0.0 (0.0-0.1) 5 0.1 (0.0-0.1) 
2002 0 0.0 (0.0-2.1) 0 0.0 (0.0-0.7) 3 0.1 (0.0-0.3) 0 0.0 (0.0-0.1) 3 0.0 (0.0-0.1) 
2003 0 0.0 (0.0-2.1) 5 0.9 (0.3-2.2) 4 0.0 (0.1-0.3) 1 0.0 (0.0-0.1) 10 0.1 (0.1-0.2) 
2004 0 0.0 (0.0-2.1) 1 0.2 (0.0-1.1) 2 0.1 (0.0-0.2) 0 0.0 (0.0-0.1) 3 0.0 (0.0-0.1) 
 
 
7.4.3 Non-type b H. influenzae 
No substantial changes were observed in annual incidences of non-type b Hi infection but a 
slight increase was seen in age groups 0-2 months in the years 1999 to 2001 and again in 
2004, and in age group 3-11 months in the years 2000 to 2002 (table 22).  
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Table 22:  Age-specific annual incidence rates per 100,000 (95% CI) of non-type b invasive 
H. influenzae disease from 1998 to 2004 
 0-2 months 3-11 months 1.0 – 4.9 years 5.0 – 9.9 years total 
 n incidence n incidence n incidence n incidence n incidence 
1998 2 1.0 (0.1-3.7) 1 0.2 (0.0-0.9) 5 0.2 (0.1-0.4) 2 0.0 (0.0-0.2) 10 0.1 (0.1-0.2) 
Capsulated 0 0.0 (0.0-1.9) 0 0.0 (0.0-0.6) 0 0.0 (0.0-0.1) 0 0.0 (0.0-0.1) 0 0.0 (0.0-0.0) 
Non-capsulated 2 1.0 (0.1-3.7) 1 0.2 (0.0-0.9) 5 0.2 (0.1-0.4) 2 0.0 (0.0-0.2) 10 0.1 (0.1-0.2) 
Not specified 0 0.0 (0.0-1.9) 0 0.0 (0.0-0.6) 0 0.0 (0.0-0.1) 0 0.0 (0.0-0.1) 0 0.0 (0.0-0.0) 
1999 5 2.6 (0.8-6.0) 2 0.3 (0.0-1.2) 7 0.2 (0.1-0.5) 0 0.0 (0.0-0.1) 14 0.2 (0.1-0.3) 
Capsulated 0 0.0 (0.0-1.9) 2 0.3 (0.0-1.2) 1 0.0 (0.0-0.2) 0 0.0 (0.0-0.1) 3 0.0 (0.0-0.1) 
Non-capsulated 5 2.6 (0.8-6.0) 0 0.0 (0.0-0.6) 6 0.2 (0.1-0.4) 0 0.0 (0.0-0.1) 11 0.1 (0.1-0.2) 
Not specified 0 0.0 (0.0-1.9) 0 0.0 (0.0-0.6) 0 0.0 (0.0-0.1) 0 0.0 (0.0-0.1) 0 0.0 (0.0-0.0) 
2000 6 3.1 (1.1-6.8) 4 0.7 (0.2-1.8) 9 0.3 (0.1-0.5) 8 0.2 (0.1-0.4) 27 0.3 (0.2-0.5) 
Capsulated 0 0.0 (0.0-1.9) 1 0.2 (0.0-1.0) 1 0.0 (0.0-0.2) 0 0.0 (0.0-0.1) 2 0.0 (0.0-0.1) 
Non-capsulated 6 3.1 (1.1-6.8) 3 0.5 (0.1-1.5) 7 0.2 (0.1-0.5) 8 0.2 (0.1-0.4) 24 0.3 (0.2-0.4) 
Not specified 0 0.0 (0.0-1.9) 0 0.0 (0.0-0.6) 1 0.0 (0.0-0.2) 0 0.0 (0.0-0.1) 1 0.0 (0.0-0.1) 
2001 5 2.7 (0.9-6.3) 6 1.1 (0.4-2.4) 9 0.3 (0.1-0.5) 3 0.1 (0.0-0.2) 23 0.3 (0.2-0.4) 
Capsulated 0 0.0 (0.0-2.0) 3 0.5 (0.1-1.6) 0 0.0 (0.0-0.1) 0 0.0 (0.0-0.1) 3 0.0 (0.0-0.1) 
Non-capsulated 5 2.7 (0.9-6.3) 3 0.5 (0.1-1.6) 8 0.3 (0.1-0.5) 3 0.1 (0.0-0.2) 19 0.2 (0.1-0.4) 
Not specified 0 0.0 (0.0-2.0) 0 0.0 (0.0-0.7) 1 0.0 (0.0-0.2) 0 0.0 (0.0-0.1) 1 0.0 (0.0-0.1) 
2002 2 1.1 (0.1-4.0) 3 0.6 (0.1-1.6) 12 0.4 (0.2-0.7) 5 0.1 (0.0-0.3) 22 0.3 (0.2-0.4) 
Capsulated 0 0.0 (0.0-2.1) 1 0.2 (0.0-1.0) 3 0.1 (0.0-0.3) 2 0.0 (0.0-0.2) 6 0.1 (0.0-0.2) 
Non-capsulated 2 1.1 (0.1-4.0) 1 0.2 (0.0-1.0) 9 0.3 (0.1-0.6) 3 0.1 (0.0-0.2) 15 0.2 (0.1-0.3) 
Not specified 0 0.0 (0.0-2.1) 1 0.2 (0.0-1.0) 0 0.0 (0.0-0.1) 0 0.0 (0.0-0.1) 1 0.0 (0.0-0.1) 
2003 3 1.7 (0.4-5.0) 2 0.4 (0.0-1.4) 7 0.2 (0.1-0.5) 3 0.1 (0.0-0.2) 15 0.2 (0.1-0.3) 
Capsulated 0 0.0 (0.0-2.1) 0 0.0 (0.0-0.7) 2 0.1 (0.0-0.2) 1 0.0 (0.0-0.1) 3 0.0 (0.0-0.1) 
Non-capsulated 3 1.7 (0.4-5.0) 2 0.4 (0.0-1.4) 5 0.2 (0.1-0.4) 2 0.1 (0.0-0.2) 12 0.2 (0.1-0.3) 
Not specified 0 0.0 (0.0-2.1) 0 0.0 (0.0-0.7) 0 0.0 (0.0-0.1) 0 0.0 (0.0-0.1) 0 0.0 (0.0-0.0) 
2004 6 3.4 (1.2-7.4) 2 0.4 (0.0-1.4) 9 0.3 (0.1-0.6) 2 0.1 (0.0-0.2) 19 0.2 (0.1-0.4) 
Capsulated 0 0.0 (0.0-2.1) 1 0.2 (0.0-1.1) 3 0.1 (0.0-0.3) 0 0.0 (0.0-0.1) 4 0.1 (0.0-0.1) 
Non-capsulated 6 3.4 (1.2-7.4) 1 0.2 (0.0-1.1) 4 0.1 (0.0-0.3) 2 0.1 (0.0-0.2) 13 0.2 (0.1-0.3) 
Not specified 0 0.0 (0.0-2.1) 0 0.0 (0.0-0.7) 2 0.1 (0.0-0.2) 0 0.0 (0.0-0.1) 2 0.0 (0.0-0.1) 
 
 
7.4.4 Adjusted incidence rates 
Correcting incidences for incompleteness of case ascertainment through both surveillance 
systems using capture-recapture estimates, nearly identical rates to those described above 
were observed (table 23):  
 
Table 23:  Estimated annual incidence rates per 100,000 (95% CI) of invasive H. influenzae 
disease by serotype from 1998 to 2004 using capture-recapture method 
Hib Non type b All Hi year 
N incidence N incidence N incidence 
1998 30 0.4 (0.2-0.5) 10 0.1 (0.1-0.2) 56 0.7 (0.5-0.9) 
1999 15 0.2 (0.1-0.3) 16 0.2 (0.1-0.3) 47 0.6 (0.4-0.8) 
2000 23 0.3 (0.2-0.4) 27 0.3 (0.2-0.5) 83 1.0 (0.8-1.3) 
2001 18 0.2 (0.1-0.4) 23 0.3 (0.2-0.4) 51 0.6 (0.5-0.8) 
2002 12 0.2 (0.1-0.3) 22 0.3 (0.2-0.4) 44 0.6 (0.4-0.7) 
2003 19 0.2 (0.1-0.4) 15 0.2 (0.1-0.3) 42 0.5 (0.4-0.7) 
2004 7 0.1 (0.0-0.2) 21 0.3 (0.2-0.4) 34 0.4 (0.3-0.6) 
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When adjusting Hib cases for changes in the proportion of Hib isolates typed over time (see 
chapter 6.4.3.2), higher incidences resulted, especially for the first two age groups (table 24). 
The highest estimated incidence rates were found in the 0-2 month age group (2.1 per 
100,000 in 2000) and in the 3-11 month age group (2.1 per 100,000 in 2003).  
 
Table 24:  Age-specific annual incidence rates per 100,000 (95% CI) of type b invasive 
H. influenzae disease from 1998 to 2004 adjusted for differences in the proportion 
of typed cases over time.  
0-2 months 3-11 months 1.0 – 4.9 years 5.0 – 9.9 years total year 
N incidence N incidence N incidence N incidence N incidence 
1998 0 0.0 (0.0-1.9) 7 1.2 (0.5-2.4) 25 0.8 (0.5-1.2) 4 0.1 (0.0-0.2) 38 0.5 (0.3-0.6) 
1999 2 1.0 (0.1-3.7) 1 0.2 (0.0-1.0) 13 0.4 (0.2-0.7) 4 0.1 (0.0-0.2) 20 0.2 (0.1-0.4) 
2000 4 2.1 (0.6-5.3) 10 1.7 (0.8-3.2) 12 0.4 (0.2-0.7) 2 0.0 (0.0-0.2) 29 0.4 (0.2-0.5) 
2001 3 1.6 (0.3-4.8) 8 1.4 (0.6-2.9) 8 0.3 (0.1-0.5) 2 0.0 (0.0-0.2) 21 0.3 (0.2-0.4) 
2002 2 1.1 (0.1-4.0) 5 0.9 (0.3-2.2) 8 0.3 (0.1-0.5) 0 0.0 (0.0-0.1) 15 0.2 (0.1-0.3) 
2003 1 0.6 (0.0-3.2) 11 2.1 (1.0-3.7) 10 0.3 (0.2-0.6) 1 0.0 (0.0-0.1) 23 0.3 (0.2-0.4) 
2004 0 0.0 (0.0-2.1) 3 0.6 (0.1-1.7) 2 0.1 (0.0-0.2) 0 0.0 (0.0-0.1) 5 0.1 (0.0-0.2) 
 
 
Since the introduction of hexavalent vaccines at the end of 2000, no increase in the 
incidence of invasive Hib disease in children could be detected in Germany. The highest 
estimated incidence rate since 1998 was seen in the 3-11 month age group in 2003, but 
confidence intervals were wide.  
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7.5 Effectiveness of hexavalent vaccines against invasive Hib 
disease (Objective 3) 
7.5.1 Cases and subcohort members contributing to effectiveness 
calculations 
7.5.1.1 Cases 
As described in the methods section the analytic approach to assess vaccine effectiveness 
was that of a case-cohort study. Cases included in the effectiveness calculations of 
hexavalent vaccines met the following criteria:  
 
- Born between 1 August 2000 and 30 June 2003 
- Aged 2 months or older 
- no vaccination or vaccination with hexavalent vaccines before onset of disease 
- confirmed systemic H. influenzae infection (type b or untyped) detected by ESPED 
until 31 December 2003 
 
Thirty-four cases met these definitions. Of these, 27 were identified as type b and 7 were not 
typed. Of the 27 Hib cases, 10 were vaccinated with hexavalent vaccines and 17 were 
unvaccinated; of the 7 untyped cases, 2 were vaccinated with hexavalent vaccines and 5 
unvaccinated. There were no cases vaccinated with a mixture of hexavalent and other Hib 
vaccines before onset of disease.  
 
Of the 10 cases vaccinated with hexavalent vaccines, 5 had received an incomplete primary 
series, and 5 had received the full primary series. None had received a booster or 2nd year 
dose. According to their age and to the German recommended vaccination schedule, 3 of the 
5 partially primed children and 3 of the 5 fully primed children could have received at least 
one additional dose before disease onset. The other four children with invasive Hib disease 
and one of the two children with untyped H. influenzae disease were defined as immunised 
according to the recommended schedule (see ‘age-eligibility of the vaccination schedule’; 
chapter 6.1.2).  
 
In table 25 vaccination histories of the 10 Hib and the 2 untyped H. influenzae cases 
vaccinated with hexavalent vaccines and eligible for effectiveness calculations are shown in 
detail.  
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Table 25:  List of all Hib and untyped Hi cases vaccinated with hexavalent vaccines from the 
ESPED surveillance system in Germany, which contributed to vaccine effectiveness 
calculations.  
vaccination history 
vaccination 1 vaccination 2 vaccination 3 case birth date (mm/year) 
age at 
disease 
(months) 
serotype 
N 
vaccin-
ation age vaccine age vaccine age vaccine 
age-eligibility 
of the 
vaccination 
schedule* 
Haemophilus influenzae type b 
32/01 8/2000 6 Type b 1 5 hexavalent - - - - not according 
6/03 7/2002 8 Type b 1 6 hexavalent - - - - not according 
25/03 11/2002 4 Type b 1 3 hexavalent - - - - according 
36/03 5/2003 4 Type b 1 3 hexavalent - - - - according  
45/03 5/2003 6 Type b 2 3 hexavalent 4 hexavalent - - not according 
2/02 11/2001 12 Type b 3 2 hexavalent 4 hexavalent 6 hexavalent according  
2/03 8/2001 17 Type b 3 3 hexavalent 5 hexavalent 7 hexavalent not according 
44/03 11/2001 23 Type b 3 4 hexavalent 5 hexavalent 8 hexavalent not according 
46/03 5/2002 17 Type b 3 3 hexavalent 5 hexavalent 8 hexavalent not according 
39/03 3/2003 7 Type b 3 2 hexavalent 3 hexavalent 4 hexavalent according  
Untyped Haemophilus influenzae 
34/02 5/2001 15 Untyped 2    2 hexavalent  12 hexavalent    - - according  
27/03 11/2001 17 Untyped 3    4 hexavalent    5 hexavalent    6 hexavalent not according 
* ‘not according’ means not according to the vaccination schedule; ‘according’ means according to the vaccination 
schedule (definition ‘age-eligibility of the vaccination schedule’; chapter 6.1.2) 
 
 
Cases with unknown serotype (cases #34/02 and #27/03 from table 25 and 5 unvaccinated 
cases) were taken into account in sensitivity analyses. Case #34/03, a 40 month old boy 
vaccinated four times with the last dose given as a hexavalent vaccine (table 13; chapter 
6.2.1.5), was not included in vaccine effectiveness calculations because he was born before 
1 August 2000.  
 
7.5.1.2 Subcohort 
According to the analytic approach of a case-cohort study to assess vaccine effectiveness, 
all infants in Germany constitute the full cohort. From the full cohort, a representative sub-
cohort was randomly sampled in the nationwide immunisation survey as described in the 
methods section.  
 
Subcohort members included in the effectiveness calculations of hexavalent vaccines met 
the following criteria:  
 
- Born between 1 August 2000 and 30 June 2003 
- Aged 2 months or older at interview  
- no vaccination or vaccination with hexavalent vaccines before onset of disease 
- interviews done until 30 January 2004 
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1112 children from the telephone surveys met these definitions. Of these, 71 (6.4%) had 
never been vaccinated against Hib at the time of the interview, 890 (80.0%) had received 
hexavalent vaccines only, and 151 (13.6%) had received mixed schedules of hexavalent and 
other Hib vaccines.  
 
Of those receiving hexavalent vaccines only, 334 (34.8%) were fully primed only and 517 
(58.1%) received 2nd year dose at the time of the interview; of those receiving mixtures of 
hexavalent Hib vaccines and other Hib vaccines, 26 (17.2%) were fully primed and 121 
(80.1%) received 2nd year dose (table 26).  
 
Table 26:  Children from the German national immunisation survey included in vaccine 
effectiveness calculations: type of vaccines used and number of doses 
administered at the time of the interview. 
Vaccination status N % 
   
Not Hib vaccinated   71 100 
Hexavalent Hib vaccines 890 100 
 1 dose priming    11    1.2 
 2 doses priming    28    3.2 
 Full priming  334  37.5 
 2nd year dose  
  full immunisation 
 517  
  447 
 58.1 
    - 
Mixed types 151 100 
 1 dose priming      0    0.0 
 2 doses priming      4    2.6 
 Full priming    26  17.2 
 2nd year dose  
  full immunisation 
 121 
  99 
 80.1 
    - 
Total 1112  
 
 
For those children receiving hexavalent vaccines only, median age (95% CI) at vaccination 
with the complete primary series of hexavalent vaccines was 6.0 (5.8-6.1) months and 
median age at vaccination with the full immunisation was 14.4 (14.1-14.8) months. This is 
later than recommended by the national immunisation guidelines: 2.0-2.9 months later than 
recommended for the primary series and at the upper recommended end for the full 
immunisation.  
 
All 151 children receiving a mixture of hexavalent and other Hib vaccines were taken into 
account in sensitivity analyses.  
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7.5.2 Estimates of hexavalent Hib vaccine effectiveness 
7.5.2.1 Vaccine effectiveness for completeness of the vaccination schedule 
The overall estimate of the effectiveness for DTaP-IPV-HB/Hib combination vaccines against 
invasive Hib was 75.5% (95% CI: 31.4-91.3) for an incomplete primary series and 91.8% 
(95% CI: 73.6-97.5) for the full primary series. For the 2nd year dose - but no full 
immunisation - and full immunisation vaccine effectiveness was 100.0% (95% CI: 99.5-100.0 
and 99.9-100.0, respectively). Table 27 shows the results of the time-to-event analysis in 
detail.  
 
Table 27:  Vaccine effectiveness of Haemophilus influenzae type b immunisation with DTaP-
IPV-HB/Hib on children born from 8/2000 through 6/2003 in Germany. Estimates, 
standard error and vaccine effectiveness from Cox regression model and robust variance 
estimates for completeness of vaccination schedule. 
Completeness of vaccination 
schedule 
N 
cases
Parameter 
estimate (ß) 
Standard 
error 
Vaccine 
effectiveness* 95% CI 
No vaccination 17 0** - 0.0%** - 
Incomplete primary series 5 -1.40631 0.52545 75.5% 31.4-91.3 
Full primary series 5 -2.50494 0.59867 91.8% 73.6-97.5 
2nd year dose,  
 but not fully immunised 0 -16.83515 0.45130 100.0% 99.5-100.0
§ 
Full immunisation 0 -16.81207 0.42775 100.0% 99.9-100.0§ 
* (1-eß) x 100% 
** reference category 
§ binominal exact confidence intervals 
 
 
7.5.2.2 Vaccine effectiveness for age-eligibility of the vaccination schedule 
The overall estimate of effectiveness for DTaP-IPV-HB/Hib combination vaccines against 
invasive Hib was 92.6% (95% CI: 77.7-97.5) for children vaccinated according to their age 
and to the German recommended vaccination schedule. Table 28 shows the results of the 
time-to-event analysis in detail.  
 
Table 28:  Vaccine effectiveness of Haemophilus influenzae type b immunisation with DTaP-
IPV-HB/Hib on children born from 8/2000 through 6/2003 in Germany. Estimates, 
standard error and vaccine effectiveness from Cox regression model and robust variance 
estimates for age-eligibility of vaccination schedule.  
Age-eligibility of vaccination 
schedule 
N 
cases
Parameter 
estimate (ß) 
Standard 
error 
Vaccine 
effectiveness* 95% CI 
      
Not according to schedule 23 0** - 0.0% - 
according to schedule 4 -2.59791 0.55939 92.6% 77.7-97.5 
* (1-eß) x 100% 
** reference category 
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Adjusting for the number of Hib vaccine doses given, the relative risk of invasive Hib disease 
for those not vaccinated to the recommended schedule was 6.5 (95% CI: 1.1-38.0).  
 
7.5.3 Sensitivity analyses 
Inclusion of  
- children with mixed vaccine schedules (mixture of DTaP-IPV-HB/Hib and other Hib 
vaccines within a child) as having received DTaP-IPV-HB/Hib vaccines (there were 
no cases but 151 children from the subcohort with mixed vaccine schedules) 
and / or  
- cases with untyped invasive H. influenzae disease - and therefore potentially 
belonging to the serotype b group - as Hib cases (cases #34/02 and #27/03 [see 
table 25]; case #34/02 was defined as ‘2nd year dose’ but is neither ‘fully primed’ nor 
‘fully immunised’) 
did not lower the point estimators of vaccine effectiveness described in the previous chapter 
for more than 0.2 percent; an exception is the point estimator for the 2nd year dose: if the one 
untyped Hi case is included in the model, point estimators were 75.9% and 81.6%, 
respectively; but confidence intervals were extremely wide, 0.0-98.4% and 0.0-98.0%, 
respectively.  
 
The results of the sensitivity analyses are shown in detail in the annex, chapter 15.2 (tables 
A1-A6).  
 
Haemophilus influenzae type b – Epidemiology and Vaccine Effectiveness in Germany H. Kalies 
 
   59
8 DISCUSSION 
Four years after the introduction of hexavalent vaccines in Germany, there was no indication 
of increasing incidence of invasive Hib disease or increasing number of Hib vaccine failures 
in children. Hexavalent vaccines continue to show the high effectiveness against invasive Hib 
disease observed for other DTaP-containing Hib vaccines in Germany (Kalies et al., 2004).  
 
8.1 H. influenzae type b disease before and after the 
introduction of hexavalent combination vaccines  
8.1.1 Cases and incidences 
The annual number of Hib cases in children under 10 year of age ranged between 14 and 28 
for the years 1998 through 2000, compared to numbers of 4 to 19 cases per year in the 
years 2001 through 2004, a time period where hexavalent vaccines had been introduced and 
gained a rapid increase on the German market. Constant annual numbers might lead to false 
conclusions if denominators are decreasing – a fact which is true for the German birth 
cohorts; but, even if considering incidences, no increase in invasive Hib disease after the 
introduction of hexavalent vaccines was detectable: annual incidence rates of Hib disease 
ranged between 0.2 to 0.3 per 100,000 in 1998 through 2000 compared to 0.1 to 0.2 per 
100,000 in 2001 to 2004 which is statistically inseparable. Considering an annual rate of 23 
per 100,000 children with invasive Hib disease before the introduction of any Hib vaccines 
(von Kries, 1997), these rates again demonstrate the success of all Hib vaccines.  
 
Data from most other European countries report comparable or slightly higher incidence 
rates (EU-Ibis, 2004). In the UK, however, an increase in the incidence of invasive Hib 
disease from 0.65 per 100,000 children younger than 5 years in 1998 to 4.6 per 100,000 in 
2002 was observed, with most cases being vaccinated (Ramsey et al., 2003). A more 
pronounced increase coincided with a switch in the distribution of combination vaccines, from 
diphtheria-tetanus-whole cell pertussis (DTwP)/Hib to DTaP/Hib at the end of 1999, as well 
as with the introduction of a concomitant meningococcal C conjugate vaccination (Trotter et 
al., 2003). An increase in the incidence of Hib meningitis and epiglottitis among vaccinated 
children was also observed in the Netherlands in 2002 (Rijkers et al., 2003), despite the 
exclusive use of monovalent Hib vaccines and the recommendation of a booster dose since 
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the introduction of Hib vaccines in 1993. Causes for this increase are not yet clear and 
further surveillance has to confirm this trend.  
 
8.1.2 Vaccine failures 
In Germany, the absolute number of Hib vaccine failures was very small, between 7 and 14 
cases per year for 1998 through 2000 and between 3 and 10 cases per year for 2001 
through 2004. Although the proportion of vaccinated Hib cases ranged between 25% in 2002 
and 75% in 2004, it should be noted that when most of the population is vaccinated, most 
cases will be vaccine failures, so a high proportion of vaccine failures is not necessarily 
indicative of declining vaccine effectiveness. Of particular importance when considering Hib 
vaccine failures in Germany is the fact that most Hib cases could have been avoided if they 
were vaccinated according to the German recommendations: almost all (92%) unvaccinated 
Hib cases were old enough to have received at least one shot of a Hib vaccine before 
disease onset if recommendations would have been followed, and 44% (definition made in 
this thesis) or even 53% (exact timing) of the vaccinated children were old enough to have 
received at least one additional shot if recommendation would have been followed. Data from 
the national immunisation survey showed that 70% - 80% of all German children were not 
vaccinated at the recommended age, are therefore under-protected and at risk of coming 
down with an invasive Hib disease. The relevance for German Health Policies to point at the 
importance of timely vaccination is evident since delayed vaccination is present for all other 
antigens as well (Kalies et al., 2006). Nevertheless, to date there are no national vaccination 
targets and implemented instruments to assess their achievements. Furthermore, there are 
no incentives or public health services to ensure that children have received recommended 
vaccinations.  
 
8.1.3 Possible biases 
Possible biases of case ascertainment were considered: response rates to both surveillance 
systems were high; nevertheless, Clinical ESPED reported fewer cases than Laboratory 
ESPED. Corrections for incompleteness of the surveillance systems using Capture 
Recapture method shows that both systems together captured a high proportion of all ‘true’ 
cases, between 75% and 97% per year. Accounting for this in the analysis, did not change 
the results. Better overall ascertainment from laboratories may reflect that laboratory results 
are coded by pathogens and not by clinical diagnosis and are therefore easier to report. The 
same observations were made in the 1998 to 2000 data on H. influenzae surveillance and in 
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another ESPED surveillance programme using the same two sources for pneumococcal 
surveillance (von Kries et al., 2000).  
 
In many surveillance systems it is very difficult to ensure consistency of case ascertainment 
over long periods of time because reporting and typing of cases changed over time. In the 
presented data reporting of H. influenzae cases remained relatively constant, but typing of 
cases changed between 1998 and 2004. The latter could only then mask a ‚true’ increase if 
typing rates would have decreased; the opposite was the case: typing rates increased 
between 1998 and 2004. In addition, after adjustment for changes in the proportion of cases 
typed over time no such increase was seen.  
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8.2 Effectiveness of hexavalent vaccines against invasive Hib 
disease 
The vaccine effectiveness estimates for hexavalent vaccines confirm the high effectiveness 
of other DTaP-containing Hib combination vaccines previously reported applying the same 
analytic approach of a case-cohort design (Kalies et al., 2004); vaccine effectiveness for 
these DTaP-(IPV)/Hib combination vaccines was 89.6% (95% CI: 67.0-96.7) for an 
incomplete primary series, 96.7% (95% CI: 87.7-99.1) for the full primary series and 98.5% 
(95% CI: 94.5-99.6) for the 2nd year dose. Although estimates for the incomplete and 
complete primary series were slightly lower for hexavalent vaccines, there was no significant 
difference for vaccine effectiveness between hexavalent and DTaP/Hib or DTaP-IPV/Hib 
vaccines (figure 14).  
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Figure 14:  Effectiveness of DTaP-(IPV)/Hib and DTaP-IPV-HB/Hib vaccines (4-5-valent vs. 6-
valent) against invasive Hib disease in German children. Point estimates with 95% 
confidence intervals; reference category = no vaccination; data for 4-5-valent vaccines 
derive from Kalies et al., 2004.  
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8.2.1 Superiority of case-cohort design 
Information from a nationwide immunisation survey and on detailed Hib case reports was 
combined to study Hib vaccine effectiveness. Similar information was used in the UK to study 
the effectiveness of meningococcal C vaccination (Balmer et al., 2002) as well as Hib 
vaccination (Ramsey et al., 2003). In both UK studies, information on the cases was 
assumed to be complete and the analytical method was referred to as the screening method 
(Farrington, 1993). The screening method can be used in situations where it is not possible 
to obtain the exact vaccination status of each child in the healthy population. It falls back on 
external sources on proportions vaccinated, normally data routinely collected for vaccination 
status in the population. Furthermore, in the screening method, it is assumed that the 
proportion of vaccinated in the population is the ‘true’ value, without variation.  
 
The present vaccine effectiveness study uses a case-cohort design where detailed 
information on Hib cases and on a subcohort of the German population through a nationwide 
immunisation survey was obtained. The utility of this approach has first been illustrated in 
analyses of Hib vaccine effectiveness among children living on a south-western Native 
American reservation during 1988-1993 (Moulton et al., 1995). This approach, which applies 
proportional hazard models to estimate the vaccine effectiveness, has the advantage of 
taking sampling variability of cases and controls into account. In addition, by modelling the 
vaccination status as a time-dependent variable, it is also possible to account for the wide 
variation in age at vaccination, the changing immunisation status of each child, and the 
overlap of age at vaccination with age at disease. This is especially important in Germany 
were a delay in vaccine uptake and a high individual variation in age at vaccination exists 
(Laubereau et al., 2001; Kalies et al., 2006) and has been confirmed by the present study; for 
example, median age at vaccination with the full primary series of hexavalent vaccines was 
6.0 months, which is 1.2 months later than the upper limit of the national recommendations, 
and completion of the full immunisation schedule ranged between ages 11.0 and 30.4 
months. The case-cohort method for estimation of vaccine effectiveness accounts for this 
high variance and delay of vaccine uptake in Germany. The case-cohort approach, however, 
requires detailed information on individuals. This information had to be obtained from the 
immunisation survey performed for this study, since the only routine estimation of vaccination 
coverage in Germany is based on school health examinations which do not assess types of 
vaccines or timing of vaccinations (Robert Koch Institute, 2005).  
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8.2.2 Possible biases 
A number of possible sources of bias were considered. Incomplete ascertainment of cases 
could have led to bias if reporting was related to the vaccination status. For the reporting 
laboratories this is unlikely since they were unaware of the vaccination history of any patient. 
For hospitals vaccinated cases would be expected to be reported more reliably than 
unvaccinated cases as breakthrough cases are known to be of interest, which would lead to 
an underestimation of vaccine effectiveness. Bias could have occurred from 
overrepresentation of hexavalent vaccinated type b cases among those not sent for typing 
and therefore possibly type b. The sensitivity analysis showed, however, that the inclusion of 
all untyped cases as type b cases did not change the estimation of vaccine effectiveness 
substantially.  
 
Response rates to the telephone surveys were 63%. These response rates are similar to 
response rates conducted in other telephone surveys in Germany or the US (Centre for 
Disease Control, 2003; Meyer et al., 2002; Rehmet et al., 2002). Comparisons with official 
data provided by the Federal Statistical Office, Germany, (2002) revealed that the sampled 
telephone interviews are representative for families with age-eligible children in Germany 
with regard to geographical and social distribution. However, children from households with 
higher income are slightly over-represented. Whether these children have differing Hib 
immunisation patterns is not known.  
 
A selection bias while recruiting parents for the vaccination interview of their child cannot be 
excluded: parents of unvaccinated children could have refused to participate in the survey 
more frequently than parents of vaccinated children. This would lead to an overestimation of 
the vaccine coverage, and an overestimation of vaccine effectiveness. School entry health 
examinations in Germany – although not complete and only available for younger birth 
cohorts where the proportion of Hib vaccinated children is known to be lower – estimate the 
proportion of children not vaccinated against Hib at about 6.6% (personal communication, Dr. 
Anette Siedler, Robert Koch Institute, Berlin, personal communication, 2003). This is 
comparable with the 5% of unvaccinated children found in the national immunisation survey 
at 2 years of age.  
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8.2.3 Causes for differing vaccine effectiveness estimates between 
UK and Germany 
In the UK, in addition to the described increase in the incidence of invasive Hib disease 
(chapter 8.1), a case-control study showed an increasing risk in fully vaccinated children with 
increasing number of DTaP/Hib doses (Mc Vernon et al., 2003). A decline of effectiveness 
over time following vaccination was shown in another study (Ramsey et al., 2003). The 
effectiveness of these DTaP/Hib vaccines following full priming was only 56.7%. In Germany 
however, a high vaccine effectiveness of DTaP-containing Hib combination vaccines was 
found (Schmitt et al., 2001; Kalies et al., 2004). As demonstrated in this thesis, effectiveness 
of hexavalent vaccines was 91.8% (95% CI: 73.6-97.5) for fully primed children.  
 
In contrast to the UK, where a three dose regimen of Hib vaccine at 2, 3 and 4 months and 
no booster are recommended, the German Vaccine Advisory Board (STIKO) recommends a 
four dose regimen at age 2, 3, 4 and a booster at 11 months. Immunising a child according to 
these recommendations leads to the high vaccine effectiveness of 92.6% (95% CI: 77.7-
97.5) found in this work, irrespective of the number of doses given. Children not vaccinated 
to these recommendations have a more than 6-fold risk (6.5 [95% CI: 1.1-38.0]) to come 
down with invasive H. influenzae disease, even if they received e.g. three hexavalent vaccine 
doses.  
 
The present data have the statistical power to differentiate between the effect of full priming 
and the additional effect of the booster dose: vaccine effectiveness of hexavalent vaccines 
for the 2nd year dose and full immunisation were slightly higher than that for fully primed 
children, and confidence intervals do not overlap with those of full priming (100.0% [95% CI: 
99.5-100.0] and 100.0% [95% CI: 99.9-100.0], respectively, vs. 91.8% [95% CI: 73.6-97.5]).  
 
Given the high number of cases in the UK that occurred after the first year of life, the present 
results suggest that the absence of a booster dose in the UK immunisation schedule might 
be a potential explanation of the reduced effectiveness of the DTaP/Hib combination 
vaccines in that country (von Kries et al., 1997). The effect of the booster dose might not only 
be related to better protection of the individual child given the booster dose but also to a 
higher level of herd immunity, as the booster dose further reduces asymptomatic carriage of 
Hib (Zepp et al., 1997). Actual data on Hib carriage rates and vaccinations status are scarce 
for Germany. Presently available unpublished data indicate that Hib carriage in school age 
children is close to 0% (Dr. Britta Gröndahl, National H. influenzae Reference Centre at the 
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Department of Paediatric Infectious Diseases, Johannes-Gutenberg-University, Mainz, 
personal communication, 2005).  
 
The recommended age for the primary series is identical in the UK and Germany, but 
considerable delay in vaccine administration has been observed in Germany (Laubereau et 
al., 2001; Kalies et al., 2006). In the subcohort described here, the median age at completion 
of the primary series of hexavalent combination vaccines was 6.0 months. It has been 
suggested that immune memory may increase with age at vaccination and with longer 
intervals between doses (Zepp et al., 1997; Vidor et al., 2001). Thus, the observed delay in 
the administration of the primary series might further influence vaccine effectiveness and 
explain the higher vaccine effectiveness in fully primed children in Germany compared with 
UK. It would have been of interest to investigate effects of age at receipt of primary or 
booster doses, but the number of immunised children was insufficient to support such 
estimates.  
 
8.3 Conclusion 
With the widespread use and rapid uptake of hexavalent combination vaccines in Germany, 
no increase in Hib cases, incidences or vaccine failures was found and high vaccine 
effectiveness against Hib for fully primed as well as for fully immunised children was 
observed.  
 
The current data are based on a relatively short follow-up after the introduction of hexavalent 
vaccines. Sustained surveillance of H. influenzae type b disease in German children is 
planned until 2007 and should confirm the protection induced by hexavalent vaccines – 
especially for fully immunised children. This persistent monitoring of H. influenzae cases 
might appear redundant; however, without monitoring of Hib cases in the UK, the apparent 
problems related to a vaccination schedule without a booster dose would not have been 
detected.  
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9 NOTATION 
CI   Confidence interval 
DTaP/Hib  Diphtheria, tetanus and acellular pertussis containing Hib vaccine 
DTwP/Hib  Diphtheria, tetanus and whole cell pertussis containing Hib vaccine 
DTaP-IPV/Hib DTaP plus inactivated poliovirus containing Hib vaccine (pentavalent 
vaccine) 
DTaP-IPV-HB/Hib DTaP-IPV plus hepatitis B containing Hib vaccine (hexavalent vaccine) 
EMEA European Agency for the Evaluation of Medicinal Products 
ESPED ‘Erhebungseinheit für seltene pädiatrische Erkrankungen in 
Deutschland’ 
Hi   Haemophilus influenzae 
Hib   Haemophilus influenzae type b 
PCR   Polymerase Chain Reaction 
RR   Relative risk 
STIKO ‘Ständige Impfkommission am Robert Koch-Institut’; German Vaccine 
Advisory Board  
UK United Kingdom 
US United States 
VE   Vaccine effectiveness 
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15 ANNEX 
15.1 Questionnaires 
Annex A.1:  Monthly report card used by Clinical ESPED 
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Annex A.2:  Questionnaire used by Clinical ESPED 
 
Erhebungseinheit für seltene pädiatrische 
Erkrankungen  in Deutschland
Forschungsstelle für pädiatrische Epidemiologie bei der Deutschen Gesellschaft für Kinderheilkunde und Jugendmedizin
Invasive Haemophilus  influenzae-Infektion (Kinder < 16 Jahre)
..................
.................
13.10.2005
.................
Klinik-IDNO:
ESPED-LNR:
Aussendedatum:
Wird von ESPED ausgefüllt!   
Eingangsdatum:
Rücksendung an  nebenstehende Adresse 
erbetenESPED
Arbeitsgruppe der Kinderklinik der
Heiunrich-Heine-Universität Düsseldorf
Postfach 10 22 44
40013   Düsseldorf
Berichtende Kinderklinik: Ansprechpartner für Rückfragen:
.........................................................................................................
........................................................................................................ Tel.: 
........................................................................................................ Fax: 
PATIENTENDATEN
Patienteninitialen: I_x_I____I  /  I_x_I____I Geburtsdatum: I____I . I_______I
2. Buchstabe Familienname Vorname Monat            Jahr
Geschlecht: weiblich Nationalität des Kindes: deutsch
männlich andere:  ....................................................
STATIONÄRE  AUFNAHME I____I . I____I . I________I
LOKALISATION
Meningitis Epiglottitis Pneumonie
sept. Arthritis Osteomyelitis Bakteriämie ohne Fokus
sonstige, welche:...........................................
Kultureller Nachweis in: Blut Liquor sonstiges........................................................
Nachweis am: I____I . I____I . I________I
Untersuchungsnr.:...............................................................................................
ß-Lactamase-Bildner: ja nein nicht geprüft
SEROTYPISIERUNG
Serotypisierung wurde nicht angestrebt
erfolgte in dem Labor, in dem der Keim angezüchtet wurde
Name/Adresse des Labors: .......................................................................
Keime weiterversandt
Name/Adresse des Labors: .......................................................................
Ergebnis der Typisierung
Nicht typisierbar
Typ b
nicht Typ b, sondern: a c d e f a – f negativ
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HIB-IMPFUNG
ja nein
Name/Anschrift des Impfarztes:................................................................................................
Datum (Tag/Monat/Jahr) Name des (Kombinations-)Impfstoffes, Charge
1. Impfung: I____I . I____I . I________I ...............................................................................
2. Impfung: I____I . I____I . I________I ............................................................……………
3. Impfung: I____I . I____I . I________I .................................................................…………
4. Impfung: I____I . I____I . I________I ................................................................................
Impfdaten erhoben aus:
Elternbefragung Einsicht in Impfausweis Anruf beim Impfarzt
Wenn Haemophilus influenzae Typ B nachgewiesen und das Kind vollständig Hib-geimpft ist: 
Wurde eine immunologische Abklärung durchgeführt?
nein
ja, welche:.............................................................................................................................. 
ANAMNESE
Bestehen anamnestische Auffälligkeiten ? ja nein
Wenn ja, welche:
Frühgeburt  in der   I___I___I. SSW
erhält immunsupressive Therapie welche:.....................................................................
bekannter Immundefekt welcher: ..................................................................
angeborene Anomalien welche: ....................................................................
Chromosomenaberration welche: ....................................................................
sonstiges  ...............................................................................................................................
ERGEBNIS
Unklar (Befunde stehen noch aus)
Völlige Ausheilung
Hörvermögen: normal pathologisch nicht geprüft
Überleben mit Restschäden (außer Hörvermögen), welche: .........................................................................
.........................................................................
..........................................................................
Tod
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 Annex A.3:  Monthly report questionnaire used by Laboratory ESPED 
 
Falldefinition:   Anzucht aus physiologisch sterilem Substrat (wie Blut, Liquor, Punktat )  
bei Kindern < 16 Jahre 
Streptococcus pneumoniae 
ja      nein  
bei Kindern < 16 Jahre 
Haemophilus influenzae 
ja      nein  
bei Säuglingen < 4 Monate 
Streptococcus agalactiae 
ja      nein  
Wenn nein, bitte Bogen trotzdem zurück! 
Wenn ja, bitte Bogen weiter ausfüllen:   
Anzahl Kinder                      mit 
 
Streptococcus pneumoniae          _____ 
Haemophilus influenzae                _____ 
Streptococcus agalactiae              _____ 
Für jedes Kind mit Befund aus o.g. sterilen Untersuchungsmaterialien werden folgende Angaben 
erbeten  
(weitere Bögen bitte unter o.a. Fax- bzw. Tel-Nr. anfordern oder kopieren): 
Ihre Untersuchungsnummer         _____________________ 
Vorname / Name 
(jeweils zweiter Buchstabe)          |_X_|___|  /  |_X_|___| 
Geschlecht  mnl.     wbl.    unbek.  
Geburtsdatum (Monat und 
Jahr) 
        |_XX_| . |___| . |________| 
Wohnort-PLZ (erste 3 Ziffern)         |___|___|___|_X_|_X_| 
Probenmaterial: 
1 Blut  2 Liquor  3 Pleura-
Punktat   
4 sonstiges (bitte angeben) 
 
      1    2    3    4  __________________________ 
Eingangsdatum der Probe         |___|. |___|. 2001 
Herkunft der Probe: 
1 Kinderklinik  2 sonst. Klinik 
3 niedergel. Arzt 
 
      1         2           3   
Materialeinsendung  zur Typisierung und Resistenzbestimmung – Stämme von ... 
Strep. pneum. an NRZ Aachen 
ja      nein  
Haem. infl. an Labor Kiel 
ja      nein  
wenn nein:  Kapseltyp |___| 
Strep. agalac. an Labor 
Freiburg 
ja      nein  
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15.2 Sensitivity analyses of vaccine effectiveness calculations 
15.2.1 Inclusion of children with mixed vaccine schedules 
Table A.1:  Vaccine effectiveness of DTaP-IPV-HB/Hib vaccines against invasive H. influenzae 
type b disease (completeness of vaccination schedule). Inclusion of children with 
mixed vaccine schedules.  
Completeness of vaccination 
schedule 
N 
cases
Parameter 
estimate (ß) 
Standard 
error 
Vaccine 
effectiveness* 95% CI 
No vaccination 17 0** - 0.0%** - 
Incomplete primary series 5 -1.55792 0.53006 78.9 40.5-92.6 
Full primary series 5 -2.62887 0.59257 92.8 77.0-97.7 
2nd year dose,  
 but not fully immunised 0 -17.23215 0.45387 100.0 99.5-100.0
§ 
Full immunisation 0 -17.20428 0.43417 100.0 99.8-100.0§ 
* (1-eß) x 100% 
** reference category 
§ binominal exact confidence intervals 
 
Table A.2:  Vaccine effectiveness of DTaP-IPV-HB/Hib vaccines against invasive H. influenzae 
type b disease (age-eligibility of vaccination schedule). Inclusion of children with 
mixed vaccine schedules.  
Age-eligibility of vaccination 
schedule 
N 
cases
Parameter 
estimate (ß) 
Standard 
error 
Vaccine 
effectiveness* 95% CI 
      
Not according to schedule 23 0** - 0.0% - 
according to schedule 4 -2.61151 0.57835 92.7 77.2-97.6 
* (1-eß) x 100% 
** reference category 
 
 
15.2.2 Inclusion of children with untyped invasive H. influenzae 
disease 
Table A.3:  Vaccine effectiveness of DTaP-IPV-HB/Hib vaccines against invasive H. influenzae 
type b disease (completeness of vaccination schedule). Inclusion of children with 
untyped invasive H. influenzae disease.  
Completeness of vaccination 
schedule 
N 
cases
Parameter 
estimate (ß) 
Standard 
error 
Vaccine 
effectiveness* 95% CI 
No vaccination 17 0** - 0.0%** - 
Incomplete primary series 5 -1.53921 0.50822 78.5 41.9-92.1 
Full primary series 5 -2.57921 0.54595 92.4 77.9-97.4 
2nd year dose,  
 but not fully immunised 0 -1.42091 1.13766 75.9 0.0-98.4 
Full immunisation 0 -16.58641 0.38481 100.0 100.0-100.0§ 
* (1-eß) x 100% 
** reference category 
§ binominal exact confidence intervals 
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Table A.4:  Vaccine effectiveness of DTaP-IPV-HB/Hib vaccines against invasive H. influenzae 
type b disease (age-eligibility of vaccination schedule). Inclusion of children with 
untyped invasive H. influenzae disease.  
Age-eligibility of vaccination 
schedule 
N 
cases
Parameter 
estimate (ß) 
Standard 
error 
Vaccine 
effectiveness* 95% CI 
      
Not according to schedule 23 0** - 0.0% - 
according to schedule 4 -2.57842 0.500735 92.4 79.5-97.2 
* (1-eß) x 100% 
** reference category 
 
 
15.2.3 Inclusion of children with untyped invasive H. influenzae 
disease and mixed vaccine schedules 
Table A.5:  Vaccine effectiveness of DTaP-IPV-HB/Hib vaccines against invasive H. influenzae 
type b disease (completeness of vaccination schedule). Inclusion of children with 
untyped invasive H. influenzae disease and mixed vaccine schedules.  
Completeness of vaccination 
schedule 
N 
cases
Parameter 
estimate (ß) 
Standard 
error 
Vaccine 
effectiveness* 95% CI 
No vaccination 17 0** - 0.0%** - 
Incomplete primary series 5 -1.69682 0.51195 81.7 50.0-93.3 
Full primary series 5 -2.71082 0.53963 93.4 80.9-97.7 
2nd year dose,  
 but not fully immunised 0 -1.69318 1.14343 81.6 0.0-98.0 
Full immunisation 0 -16.60254 0.39130 100.0 100.0-100.0§ 
* (1-eß) x 100% 
** reference category 
§ binominal exact confidence intervals 
 
Table A.6:  Vaccine effectiveness of DTaP-IPV-HB/Hib vaccines against invasive H. influenzae 
type b disease (age-eligibility of vaccination schedule). Inclusion of children with 
untyped invasive H. influenzae disease and mixed vaccine schedules.  
Age-eligibility of vaccination 
schedule 
N 
cases
Parameter 
estimate (ß) 
Standard 
error 
Vaccine 
effectiveness* 95% CI 
      
Not according to schedule 23 0** - 0.0% - 
according to schedule 4 -2.59458 0.50875 92.5 79.8-97.2 
* (1-eß) x 100% 
** reference category 
 
 
 
 
 
